Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Lung Cancer

  Free Subscription


Articles published in PLoS One

Retrieve available abstracts of 578 articles:
HTML format



Single Articles


    January 2021
  1. FINNEGAN RN, Orlandini L, Liao X, Yin J, et al
    Feasibility of using a novel automatic cardiac segmentation algorithm in the clinical routine of lung cancer patients.
    PLoS One. 2021;16:e0245364.
    PubMed     Abstract available


  2. EL-TURK N, Chou MSH, Ting NCH, Girgis A, et al
    Treatment burden experienced by patients with lung cancer.
    PLoS One. 2021;16:e0245492.
    PubMed     Abstract available


  3. LAYTRAGOON LEWIN N, Karlsson JE, Robinsson D, Fagerberg M, et al
    Influence of single nucleotide polymorphisms among cigarette smoking and non-smoking patients with coronary artery disease, urinary bladder cancer and lung cancer.
    PLoS One. 2021;16:e0243084.
    PubMed     Abstract available


  4. FUNG AS, Kopciuk K, Dean ML, D'Silva A, et al
    CXCR4 expression in lung carcinogenesis: Evaluating gender-specific differences in survival outcomes based on CXCR4 expression in early stage non-small cell lung cancer patients.
    PLoS One. 2021;16:e0241240.
    PubMed     Abstract available


  5. PATIL NS, Zou W, Mocci S, Sandler A, et al
    C-reactive protein reduction post treatment is associated with improved survival in atezolizumab (anti-PD-L1) treated non-small cell lung cancer patients.
    PLoS One. 2021;16:e0246486.
    PubMed     Abstract available


  6. MAPANGA W, Norris SA, Chen WC, Blanchard C, et al
    Consensus study on the health system and patient-related barriers for lung cancer management in South Africa.
    PLoS One. 2021;16:e0246716.
    PubMed     Abstract available


  7. LEI Z, Yang W, Zuo Y
    Beta-blocker and survival in patients with lung cancer: A meta-analysis.
    PLoS One. 2021;16:e0245773.
    PubMed     Abstract available


  8. YOU JHS, Cho WCS, Ming WK, Li YC, et al
    EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong - A cost-effectiveness analysis.
    PLoS One. 2021;16:e0247860.
    PubMed     Abstract available


  9. YU G, Cai Q, Xu X, Shen Y, et al
    Anlotinib-containing regimen for advanced small-cell lung cancer: A protocol of meta-analysis.
    PLoS One. 2021;16:e0247494.
    PubMed     Abstract available


  10. BURNETT H, Emich H, Carroll C, Stapleton N, et al
    Epidemiological and clinical burden of EGFR Exon 20 insertion in advanced non-small cell lung cancer: A systematic literature review.
    PLoS One. 2021;16:e0247620.
    PubMed     Abstract available


  11. SIGEL K, Kong CY, Rehmani S, Bates S, et al
    Optimal treatment strategies for stage I non-small cell lung cancer in veterans with pulmonary and cardiac comorbidities.
    PLoS One. 2021;16:e0248067.
    PubMed     Abstract available


  12. WANG S, Yang X, Wang W, Zhang Y, et al
    Interpretation of the absorbed constituents and pharmacological effect of Spica Schizonepetae extract on non-small cell lung cancer.
    PLoS One. 2021;16:e0248700.
    PubMed     Abstract available


  13. BERNHARDSON BM, Tishelman C, Rasmussen BH, Hajdarevic S, et al
    Sensations, symptoms, and then what? Early bodily experiences prior to diagnosis of lung cancer.
    PLoS One. 2021;16:e0249114.
    PubMed     Abstract available


  14. HUH DA, Kang MS, Lee J, Choi JY, et al
    Occupational and environmental asbestos exposure and the risk of lung cancer in Korea: A case-control study in South Chungcheong Province of Korea.
    PLoS One. 2021;16:e0249790.
    PubMed     Abstract available


  15. NGUYEN RH, Vater LB, Timsina LR, Durm GA, et al
    Impact of smoke-free ordinance strength on smoking prevalence and lung cancer incidence.
    PLoS One. 2021;16:e0250285.
    PubMed     Abstract available


  16. DUMONT-LEBLOND N, Veillette M, Racine C, Joubert P, et al
    Non-small cell lung cancer microbiota characterization: Prevalence of enteric and potentially pathogenic bacteria in cancer tissues.
    PLoS One. 2021;16:e0249832.
    PubMed     Abstract available


  17. GOLDBERG E, Ievari-Shariati S, Kidane B, Kim J, et al
    Comparative metabolomics studies of blood collected in streck and heparin tubes from lung cancer patients.
    PLoS One. 2021;16:e0249648.
    PubMed     Abstract available


  18. NINOMIYA K, Arimura H, Chan WY, Tanaka K, et al
    Robust radiogenomics approach to the identification of EGFR mutations among patients with NSCLC from three different countries using topologically invariant Betti numbers.
    PLoS One. 2021;16:e0244354.
    PubMed     Abstract available


  19. PENG H, Sun H, Guo Y
    3D multi-scale deep convolutional neural networks for pulmonary nodule detection.
    PLoS One. 2021;16:e0244406.
    PubMed     Abstract available


  20. CAHUANA PINTO RSM, Castro Panzenhagen A, Silva Oliveira LF, Fonseca Moreira JC, et al
    Incidence of lung cancer and mortality among civil construction industry workers: A protocol for a systematic review and meta-analysis.
    PLoS One. 2021;16:e0250377.
    PubMed     Abstract available


  21. AYE PS, McKeage MJ, Tin Tin S, Khwaounjoo P, et al
    Population-based incidence rates and increased risk of EGFR mutated non-small cell lung cancer in Maori and Pacifica in New Zealand.
    PLoS One. 2021;16:e0251357.
    PubMed     Abstract available


  22. HO LJ, Yang HY, Chung CH, Chang WC, et al
    Increased risk of secondary lung cancer in patients with tuberculosis: A nationwide, population-based cohort study.
    PLoS One. 2021;16:e0250531.
    PubMed     Abstract available


  23. SAYANI A, Vahabi M, O'Brien MA, Liu G, et al
    Advancing health equity in cancer care: The lived experiences of poverty and access to lung cancer screening.
    PLoS One. 2021;16:e0251264.
    PubMed     Abstract available


  24. ALWITHENANI A, Bethune D, Castonguay M, Drucker A, et al
    Profiling non-small cell lung cancer reveals that PD-L1 is associated with wild type EGFR and vascular invasion, and immunohistochemistry quantification of PD-L1 correlates weakly with RT-qPCR.
    PLoS One. 2021;16:e0251080.
    PubMed     Abstract available


  25. DANG X, Zhao W, Li C, Yang H, et al
    Impact of COL6A4P2 gene polymorphisms on the risk of lung cancer: A case-control study.
    PLoS One. 2021;16:e0252082.
    PubMed     Abstract available


  26. ALLEN KL, Cann J, Zhao W, Peterson N, et al
    Correction: Upregulation of annexin A1 protein expression in the intratumoral vasculature of human non-small-cell lung carcinoma and rodent tumor models.
    PLoS One. 2021;16:e0252060.
    PubMed     Abstract available


  27. GOFFIN JR, Corriveau S, Tang GH, Pond GR, et al
    Management and outcomes of patients with chronic obstructive lung disease and lung cancer in a public healthcare system.
    PLoS One. 2021;16:e0251886.
    PubMed     Abstract available


  28. HEILBRONER SP, Xanthopoulos EP, Buono D, Carrier D, et al
    Efficacy and cost of high-frequency IGRT in elderly stage III non-small-cell lung cancer patients.
    PLoS One. 2021;16:e0252053.
    PubMed     Abstract available


  29. BARATA F, Fidalgo P, Figueiredo S, Tonin FS, et al
    Limitations and perceived delays for diagnosis and staging of lung cancer in Portugal: A nationwide survey analysis.
    PLoS One. 2021;16:e0252529.
    PubMed     Abstract available


  30. STEFANI D, Hegedues B, Collaud S, Zaatar M, et al
    Torque Teno Virus load in lung cancer patients correlates with age but not with tumor stage.
    PLoS One. 2021;16:e0252304.
    PubMed     Abstract available


  31. FRANCO F, Carcereny E, Guirado M, Ortega AL, et al
    Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry.
    PLoS One. 2021;16:e0251761.
    PubMed     Abstract available


  32. ROUNIS K, Makrakis D, Papadaki C, Monastirioti A, et al
    Prediction of outcome in patients with non-small cell lung cancer treated with second line PD-1/PDL-1 inhibitors based on clinical parameters: Results from a prospective, single institution study.
    PLoS One. 2021;16:e0252537.
    PubMed     Abstract available


  33. NG WW, Lin CC, Cheng CY, Jiang JS, et al
    Real-world outcomes of first- and second-generation tyrosine kinase inhibitors first-line in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer: A retrospective observational cohort study.
    PLoS One. 2021;16:e0253335.
    PubMed     Abstract available


  34. IKAWA T, Tabuchi T, Konishi K, Morimoto M, et al
    Prolonged overall treatment time negatively affects the outcomes of stereotactic body radiotherapy for early-stage non-small-cell lung cancer: A propensity score-weighted, single-center analysis.
    PLoS One. 2021;16:e0253203.
    PubMed     Abstract available


  35. TSAKANOVA G, Stepanyan A, Arakelova E, Ayvazyan V, et al
    The radioenhancement potential of Schiff base derived copper (II) compounds against lung carcinoma in vitro.
    PLoS One. 2021;16:e0253553.
    PubMed     Abstract available


  36. WRIGHT GM, Gimbrone NT, Sarcar B, Percy TR, et al
    CDK4/6 inhibition synergizes with inhibition of P21-Activated Kinases (PAKs) in lung cancer cell lines.
    PLoS One. 2021;16:e0252927.
    PubMed     Abstract available


  37. CHUNG HS, Bae S, Kim I, Ahn HY, et al
    Unexpected exposure to Mycobacterium tuberculosis during bronchoscopy using radial probe endobronchial ultrasound.
    PLoS One. 2021;16:e0246371.
    PubMed     Abstract available


  38. CHEN DT, Chan W, Thompson ZJ, Thapa R, et al
    Utilization of target lesion heterogeneity for treatment efficacy assessment in late stage lung cancer.
    PLoS One. 2021;16:e0252041.
    PubMed     Abstract available


  39. BOROWICZ S, Principe DR, Dorman MJ, McHenry AJ, et al
    HAI-1 is an independent predictor of lung cancer mortality and is required for M1 macrophage polarization.
    PLoS One. 2021;16:e0252197.
    PubMed     Abstract available


  40. FUCHS J, Fruh M, Papachristofilou A, Bubendorf L, et al
    Resection of isolated brain metastases in non-small cell lung cancer (NSCLC) patients - evaluation of outcome and prognostic factors: A retrospective multicenter study.
    PLoS One. 2021;16:e0253601.
    PubMed     Abstract available


  41. XIAO K, Liu S, Xiao Y, Wang Y, et al
    Bioinformatics prediction of differential miRNAs in non-small cell lung cancer.
    PLoS One. 2021;16:e0254854.
    PubMed     Abstract available


  42. PEDERSEN S, Kristensen AF, Falkmer U, Christiansen G, et al
    Increased activity of procoagulant factors in patients with small cell lung cancer.
    PLoS One. 2021;16:e0253613.
    PubMed     Abstract available


  43. ARIK A, Dodd E, Cairns A, Streftaris G, et al
    Socioeconomic disparities in cancer incidence and mortality in England and the impact of age-at-diagnosis on cancer mortality.
    PLoS One. 2021;16:e0253854.
    PubMed     Abstract available



  44. Correction: Utilization of target lesion heterogeneity for treatment efficacy assessment in late stage lung cancer.
    PLoS One. 2021;16:e0255429.
    PubMed     Abstract available


  45. STIEB DM, Berjawi R, Emode M, Zheng C, et al
    Systematic review and meta-analysis of cohort studies of long term outdoor nitrogen dioxide exposure and mortality.
    PLoS One. 2021;16:e0246451.
    PubMed     Abstract available


    January 2020
  46. SIVIGNON M, Monnier R, Tehard B, Roze S, et al
    Cost-effectiveness of alectinib compared to crizotinib for the treatment of first-line ALK+ advanced non-small-cell lung cancer in France.
    PLoS One. 2020;15:e0226196.
    PubMed     Abstract available


  47. CRISS SD, Palazzo L, Watson TR, Paquette AM, et al
    Cost-effectiveness of pembrolizumab for advanced non-small cell lung cancer patients with varying comorbidity burden.
    PLoS One. 2020;15:e0228288.
    PubMed     Abstract available



  48. Retraction: Immunoglobulin G Expression in Lung Cancer and Its Effects on Metastasis.
    PLoS One. 2020;15:e0228444.
    PubMed    


  49. YANG LT, Ma F, Zeng HT, Zhao M, et al
    Restoration of Mal overcomes the defects of apoptosis in lung cancer cells.
    PLoS One. 2020;15:e0227634.
    PubMed     Abstract available


  50. LU J, Zang H, Zheng H, Zhan Y, et al
    Overexpression of p-Akt, p-mTOR and p-eIF4E proteins associates with metastasis and unfavorable prognosis in non-small cell lung cancer.
    PLoS One. 2020;15:e0227768.
    PubMed     Abstract available


  51. TUVDENDORJ A, Feenstra T, Tseveen B, Buskens E, et al
    Smoking-attributable burden of lung cancer in Mongolia a data synthesis study on differences between men and women.
    PLoS One. 2020;15:e0229090.
    PubMed     Abstract available


  52. MILIAN L, Mata M, Alcacer J, Oliver M, et al
    Cannabinoid receptor expression in non-small cell lung cancer. Effectiveness of tetrahydrocannabinol and cannabidiol inhibiting cell proliferation and epithelial-mesenchymal transition in vitro.
    PLoS One. 2020;15:e0228909.
    PubMed     Abstract available


  53. MAMBETSARIEV I, Wang Y, Chen C, Nadaf S, et al
    Precision medicine and actionable alterations in lung cancer: A single institution experience.
    PLoS One. 2020;15:e0228188.
    PubMed     Abstract available


  54. ELLIOTT J, Bai Z, Hsieh SC, Kelly SE, et al
    ALK inhibitors for non-small cell lung cancer: A systematic review and network meta-analysis.
    PLoS One. 2020;15:e0229179.
    PubMed     Abstract available


  55. KONERT T, Everitt S, La Fontaine MD, van de Kamer JB, et al
    Robust, independent and relevant prognostic 18F-fluorodeoxyglucose positron emission tomography radiomics features in non-small cell lung cancer: Are there any?
    PLoS One. 2020;15:e0228793.
    PubMed     Abstract available


  56. CUBILLOS-ANGULO JM, Fukutani ER, Cruz LAB, Arriaga MB, et al
    Systems biology analysis of publicly available transcriptomic data reveals a critical link between AKR1B10 gene expression, smoking and occurrence of lung cancer.
    PLoS One. 2020;15:e0222552.
    PubMed     Abstract available


  57. LU G, Zhang Y
    Long non-coding RNA ATB promotes human non-small cell lung cancer proliferation and metastasis by suppressing miR-141-3p.
    PLoS One. 2020;15:e0229118.
    PubMed     Abstract available


  58. TSUKUMO Y, Naito M, Suzuki T
    Influence of EGFR-activating mutations on sensitivity to tyrosine kinase inhibitors in a KRAS mutant non-small cell lung cancer cell line.
    PLoS One. 2020;15:e0229712.
    PubMed     Abstract available


  59. BOBBILI P, Ryan K, DerSarkissian M, Dua A, et al
    Predictors of chemoradiotherapy versus single modality therapy and overall survival among patients with unresectable, stage III non-small cell lung cancer.
    PLoS One. 2020;15:e0230444.
    PubMed     Abstract available


  60. CHO MS, Park CH, Lee S, Park HS, et al
    Clinicopathological parameters for circulating tumor DNA shedding in surgically resected non-small cell lung cancer with EGFR or KRAS mutation.
    PLoS One. 2020;15:e0230622.
    PubMed     Abstract available


  61. LU Y, Jiang J, Ren C
    The clinicopathological and prognostic value of the pretreatment neutrophil-to-lymphocyte ratio in small cell lung cancer: A meta-analysis.
    PLoS One. 2020;15:e0230979.
    PubMed     Abstract available


  62. CHANG PH, Lin CR, Lee YH, Liu YL, et al
    Exercise experiences in patients with metastatic lung cancer: A qualitative approach.
    PLoS One. 2020;15:e0230188.
    PubMed     Abstract available


  63. ZHANG Y, Pavlov A, Malik S, Chen H, et al
    Efficacy of a small molecule inhibitor of the transcriptional cofactor PC4 in prevention and treatment of non-small cell lung cancer.
    PLoS One. 2020;15:e0230670.
    PubMed     Abstract available


  64. VON ITZSTEIN MS, Gupta A, Kernstine KH, Mara KC, et al
    Increased reporting but decreased mortality associated with adverse events in patients undergoing lung cancer surgery: Competing forces in an era of heightened focus on care quality?
    PLoS One. 2020;15:e0231258.
    PubMed     Abstract available


  65. YOON HJ, Kang J, Park H, Sohn I, et al
    Deciphering the tumor microenvironment through radiomics in non-small cell lung cancer: Correlation with immune profiles.
    PLoS One. 2020;15:e0231227.
    PubMed     Abstract available


  66. COOK GW, Benton MG, Akerley W, Mayhew GF, et al
    Structural variation and its potential impact on genome instability: Novel discoveries in the EGFR landscape by long-read sequencing.
    PLoS One. 2020;15:e0226340.
    PubMed     Abstract available


  67. STEINER B, Ferrucci LM, Mirabello L, Lan Q, et al
    Association between coffee drinking and telomere length in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
    PLoS One. 2020;15:e0226972.
    PubMed     Abstract available


  68. HYUN DG, Choi CM, Lee DH, Kim SW, et al
    Outcomes according to initial and subsequent therapies following intracranial progression in patients with EGFR-mutant lung cancer and brain metastasis.
    PLoS One. 2020;15:e0231546.
    PubMed     Abstract available


  69. SANCHEZ-CARPINTERO ABAD M, Sanchez-Salcedo P, de-Torres JP, Alcaide AB, et al
    Prevalence and burden of bronchiectasis in a lung cancer screening program.
    PLoS One. 2020;15:e0231204.
    PubMed     Abstract available


  70. NIU QL, Sun H, Liu C, Li J, et al
    Croton tiglium essential oil compounds have anti-proliferative and pro-apoptotic effects in A549 lung cancer cell lines.
    PLoS One. 2020;15:e0231437.
    PubMed     Abstract available



  71. Retraction: Identification and Characterization of Cells with Cancer Stem Cell Properties in Human Primary Lung Cancer Cell Lines.
    PLoS One. 2020;15:e0232726.
    PubMed    


  72. NYGARD L, Ahlborn LB, Persson GF, Chandrananda D, et al
    Circulating cell free DNA during definitive chemo-radiotherapy in non-small cell lung cancer patients - initial observations.
    PLoS One. 2020;15:e0231884.
    PubMed     Abstract available


  73. RUIYING C, Zeyun L, Yongliang Y, Zijia Z, et al
    A comprehensive analysis of metabolomics and transcriptomics in non-small cell lung cancer.
    PLoS One. 2020;15:e0232272.
    PubMed     Abstract available


  74. BLOCKER SJ, Holbrook MD, Mowery YM, Sullivan DC, et al
    The impact of respiratory gating on improving volume measurement of murine lung tumors in micro-CT imaging.
    PLoS One. 2020;15:e0225019.
    PubMed     Abstract available


  75. LIM JH, Choi JY, Im Y, Yoo H, et al
    Prognostic value of SUVmax on 18F-fluorodeoxyglucose PET/CT scan in patients with malignant pleural mesothelioma.
    PLoS One. 2020;15:e0229299.
    PubMed     Abstract available


  76. JUSTO N, Nilsson J, Korytowsky B, Dalen J, et al
    Retrospective observational cohort study on innovation in oncology and progress in survival: How far have we gotten in the two decades of treating patients with advanced non-small cell lung cancer as a single population?
    PLoS One. 2020;15:e0232669.
    PubMed     Abstract available


  77. LU Y, Liu X, Zhang E, Kopras EJ, et al
    Estrogen activates pyruvate kinase M2 and increases the growth of TSC2-deficient cells.
    PLoS One. 2020;15:e0228894.
    PubMed     Abstract available


  78. BARR MP, Gray SG, Hoffmann AC, Hilger RA, et al
    Correction: Generation and Characterisation of Cisplatin-Resistant Non-Small Cell Lung Cancer Cell Lines Displaying a Stem-Like Signature.
    PLoS One. 2020;15:e0233739.
    PubMed     Abstract available


  79. MIN KW, Kim WS, Kim DH, Son BK, et al
    High polymerase epsilon expression associated with increased CD8+T cells improves survival in patients with non-small cell lung cancer.
    PLoS One. 2020;15:e0233066.
    PubMed     Abstract available


  80. WALLRABENSTEIN T, Del Rio J, Templeton AJ, Buess M, et al
    Much has changed in the last decade except overall survival: A Swiss single center analysis of treatment and survival in patients with stage IV non-small cell lung cancer.
    PLoS One. 2020;15:e0233768.
    PubMed     Abstract available


  81. BANGAOIL R, Santillan A, Angeles LM, Abanilla L, et al
    ATR-FTIR spectroscopy as adjunct method to the microscopic examination of hematoxylin and eosin-stained tissues in diagnosing lung cancer.
    PLoS One. 2020;15:e0233626.
    PubMed     Abstract available


  82. KANG S, Kim TH, Shin JM, Han K, et al
    Optimization of a chest computed tomography protocol for detecting pure ground glass opacity nodules: A feasibility study with a computer-assisted detection system and a lung cancer screening phantom.
    PLoS One. 2020;15:e0232688.
    PubMed     Abstract available


  83. ALLEN KL, Cann J, Zhao W, Peterson N, et al
    Upregulation of annexin A1 protein expression in the intratumoral vasculature of human non-small-cell lung carcinoma and rodent tumor models.
    PLoS One. 2020;15:e0234268.
    PubMed     Abstract available


  84. CHEN R, Lin J
    Identification of feature risk pathways of smoking-induced lung cancer based on SVM.
    PLoS One. 2020;15:e0233445.
    PubMed     Abstract available


  85. YOON HY, Ryu JS, Sim YS, Kim D, et al
    Clinical significance of EGFR mutation types in lung adenocarcinoma: A multi-centre Korean study.
    PLoS One. 2020;15:e0228925.
    PubMed     Abstract available


  86. LI B, Dai C, Wang L, Deng H, et al
    A novel drug repurposing approach for non-small cell lung cancer using deep learning.
    PLoS One. 2020;15:e0233112.
    PubMed     Abstract available


  87. MU Q, Yu J, Griffin JI, Wu Y, et al
    Novel drug combination nanoparticles exhibit enhanced plasma exposure and dose-responsive effects on eliminating breast cancer lung metastasis.
    PLoS One. 2020;15:e0228557.
    PubMed     Abstract available


  88. TERAMOTO A, Tsukamoto T, Yamada A, Kiriyama Y, et al
    Deep learning approach to classification of lung cytological images: Two-step training using actual and synthesized images by progressive growing of generative adversarial networks.
    PLoS One. 2020;15:e0229951.
    PubMed     Abstract available


  89. KEMBOU NZALE S, Weeks WB, Ouafik L, Rouquette I, et al
    Inequity in access to personalized medicine in France: Evidences from analysis of geo variations in the access to molecular profiling among advanced non-small-cell lung cancer patients: Results from the IFCT Biomarkers France Study.
    PLoS One. 2020;15:e0234387.
    PubMed     Abstract available


  90. CHEN R, Lin J
    Correction: Identification of feature risk pathways of smoking-induced lung cancer based on SVM.
    PLoS One. 2020;15:e0235854.
    PubMed     Abstract available


  91. STEINHAUSER MOTTA JP, Steffen RE, Samary Lobato C, Souza Mendonca V, et al
    Endobronchial ultrasound-guided transbronchial needle aspiration versus mediastinoscopy for mediastinal staging of lung cancer: A systematic review of economic evaluation studies.
    PLoS One. 2020;15:e0235479.
    PubMed     Abstract available


  92. SONG MJ, Kim DJ, Paik HC, Cho S, et al
    Impact of idiopathic pulmonary fibrosis on recurrence after surgical treatment for stage I-III non-small cell lung cancer.
    PLoS One. 2020;15:e0235126.
    PubMed     Abstract available


  93. LOPEZ-GARCIA G, Jerez JM, Franco L, Veredas FJ, et al
    Transfer learning with convolutional neural networks for cancer survival prediction using gene-expression data.
    PLoS One. 2020;15:e0230536.
    PubMed     Abstract available


  94. WITNEY TH, Fortt R, Aboagye EO
    Correction: Preclinical Assessment of Carboplatin Treatment Efficacy in Lung Cancer by 18F-ICMT-11-Positron Emission Tomography.
    PLoS One. 2020;15:e0235804.
    PubMed     Abstract available


  95. ABE T, Nakashima C, Sato A, Harada Y, et al
    Origin of circulating free DNA in patients with lung cancer.
    PLoS One. 2020;15:e0235611.
    PubMed     Abstract available


  96. YANG SC, Lai WW, Hsu JC, Su WC, et al
    Comparative effectiveness and cost-effectiveness of three first-line EGFR-tyrosine kinase inhibitors: Analysis of real-world data in a tertiary hospital in Taiwan.
    PLoS One. 2020;15:e0231413.
    PubMed     Abstract available


  97. SMEDA M, Kij A, Proniewski B, Matyjaszczyk-Gwarda K, et al
    Unexpected effects of long-term treatment with acetylsalicylic acid on late phase of pulmonary metastasis in murine model of orthotopic breast cancer.
    PLoS One. 2020;15:e0230520.
    PubMed     Abstract available


  98. LI Y, He CL, Li WX, Zhang RX, et al
    Transcriptome analysis reveals gender-specific differences in overall metabolic response of male and female patients in lung adenocarcinoma.
    PLoS One. 2020;15:e0230796.
    PubMed     Abstract available


  99. CHOI HD, Chang MJ
    Eye, hepatobiliary, and renal disorders of erlotinib in patients with non-small-cell lung cancer: A meta-analysis.
    PLoS One. 2020;15:e0234818.
    PubMed     Abstract available


  100. LEE CY, Fujino K, Motooka Y, Gregor A, et al
    Photoacoustic imaging to localize indeterminate pulmonary nodules: A preclinical study.
    PLoS One. 2020;15:e0231488.
    PubMed     Abstract available


  101. WARSAVAGE T JR, Xing F, Baron AE, Feser WJ, et al
    Quantifying the incremental value of deep learning: Application to lung nodule detection.
    PLoS One. 2020;15:e0231468.
    PubMed     Abstract available


  102. WANG C, Zhang J, Zhou S, Yu L, et al
    Tentative identification of gefitinib metabolites in non-small-cell lung cancer patient plasma using ultra-performance liquid chromatography coupled with triple quadrupole time-of-flight mass spectrometry.
    PLoS One. 2020;15:e0236523.
    PubMed     Abstract available


  103. KIM N, Kim JS, Geol Lee C
    Predictive value of interim 18F-FDG-PET in patients with non-small cell lung cancer treated with definitive radiation therapy.
    PLoS One. 2020;15:e0236350.
    PubMed     Abstract available


  104. GASILINA A, Premnauth G, Gurjar P, Biesiada J, et al
    IODVA1, a guanidinobenzimidazole derivative, targets Rac activity and Ras-driven cancer models.
    PLoS One. 2020;15:e0229801.
    PubMed     Abstract available


  105. RIBEIRO TB, Buss L, Wayant C, Nobre MRC, et al
    Comparison of FDA accelerated vs regular pathway approvals for lung cancer treatments between 2006 and 2018.
    PLoS One. 2020;15:e0236345.
    PubMed     Abstract available



  106. Retraction: Histone Deacetylase Inhibitors Sensitize Lung Cancer Cells to Hyperthermia: Involvement of Ku70/SirT-1 in Thermo-Protection.
    PLoS One. 2020;15:e0237589.
    PubMed    


  107. FORSYTHE ML, Alwithenani A, Bethune D, Castonguay M, et al
    Molecular profiling of non-small cell lung cancer.
    PLoS One. 2020;15:e0236580.
    PubMed     Abstract available


  108. QIAN C, Liu H, Feng Y, Meng S, et al
    Clinical characteristics and risk of second primary lung cancer after cervical cancer: A population-based study.
    PLoS One. 2020;15:e0231807.
    PubMed     Abstract available


  109. ARIK A, Dodd E, Streftaris G
    Cancer morbidity trends and regional differences in England-A Bayesian analysis.
    PLoS One. 2020;15:e0232844.
    PubMed     Abstract available


  110. KANG JK, Heo S, Kim HP, Song SH, et al
    Liquid biopsy-based tumor profiling for metastatic colorectal cancer patients with ultra-deep targeted sequencing.
    PLoS One. 2020;15:e0232754.
    PubMed     Abstract available


  111. LEVEQUE E, Lacourt A, Philipps V, Luce D, et al
    A new trajectory approach for investigating the association between an environmental or occupational exposure over lifetime and the risk of chronic disease: Application to smoking, asbestos, and lung cancer.
    PLoS One. 2020;15:e0236736.
    PubMed     Abstract available


  112. MEIKLE CK, Meisler AJ, Bird CM, Jeffries JA, et al
    Platelet-T cell aggregates in lung cancer patients: Implications for thrombosis.
    PLoS One. 2020;15:e0236966.
    PubMed     Abstract available


  113. GRATZ M, Ruhlmann V, Umutlu L, Fenchel M, et al
    Impact of respiratory motion correction on lesion visibility and quantification in thoracic PET/MR imaging.
    PLoS One. 2020;15:e0233209.
    PubMed     Abstract available


  114. NASRI NASRABADI P, Nayeri Z, Gharib E, Salmanipour R, et al
    Establishment of a CALU, AURKA, and MCM2 gene panel for discrimination of metastasis from primary colon and lung cancers.
    PLoS One. 2020;15:e0233717.
    PubMed     Abstract available


  115. KLINGLER A, Regensburger D, Tenkerian C, Britzen-Laurent N, et al
    Species-, organ- and cell-type-dependent expression of SPARCL1 in human and mouse tissues.
    PLoS One. 2020;15:e0233422.
    PubMed     Abstract available


  116. LARSON KL, Huang B, Chen Q, Tucker T, et al
    EGFR testing and erlotinib use in non-small cell lung cancer patients in Kentucky.
    PLoS One. 2020;15:e0237790.
    PubMed     Abstract available


  117. PARK KY, Kim J
    Cyclic pentapeptide cRGDfK enhances the inhibitory effect of sunitinib on TGF-beta1-induced epithelial-to-mesenchymal transition in human non-small cell lung cancer cells.
    PLoS One. 2020;15:e0232917.
    PubMed     Abstract available


  118. LU JJ, Li P, Yang Y, Wang L, et al
    Prognostic value of LAT-1 status in solid cancer: A systematic review and meta-analysis.
    PLoS One. 2020;15:e0233629.
    PubMed     Abstract available


  119. KIM MS, Kim SH, Yang SH, Kim MS, et al
    Restricting extracellular Ca2+ on gefitinib-resistant non-small cell lung cancer cells reverses altered epidermal growth factor-mediated Ca2+ response, which consequently enhances gefitinib sensitivity.
    PLoS One. 2020;15:e0238155.
    PubMed     Abstract available


  120. CHEN JL, Wu JN, Lv XD, Yang QC, et al
    The value of red blood cell distribution width, neutrophil-to-lymphocyte ratio, and hemoglobin-to-red blood cell distribution width ratio in the progression of non-small cell lung cancer.
    PLoS One. 2020;15:e0237947.
    PubMed     Abstract available


  121. REMON J, Swalduz A, Planchard D, Ortiz-Cuaran S, et al
    Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay.
    PLoS One. 2020;15:e0234302.
    PubMed     Abstract available


  122. SANTOS-SANCHEZ V, Cordoba-Dona JA, Viciana F, Escolar-Pujolar A, et al
    Geographical variations in cancer mortality and social inequalities in southern Spain (Andalusia). 2002-2013.
    PLoS One. 2020;15:e0233397.
    PubMed     Abstract available


  123. FU L, Wang H, Wei D, Wang B, et al
    The value of CEP55 gene as a diagnostic biomarker and independent prognostic factor in LUAD and LUSC.
    PLoS One. 2020;15:e0233283.
    PubMed     Abstract available


  124. DING H, Xin W, Tong Y, Sun J, et al
    Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: A systematic review.
    PLoS One. 2020;15:e0238536.
    PubMed     Abstract available


  125. SUTTON AJ, Sagoo GS, Jackson L, Fisher M, et al
    Cost-effectiveness of a new autoantibody test added to Computed Tomography (CT) compared to CT surveillance alone in the diagnosis of lung cancer amongst patients with indeterminate pulmonary nodules.
    PLoS One. 2020;15:e0237492.
    PubMed     Abstract available


  126. GOLDSBURY DE, Weber MF, Yap S, Rankin NM, et al
    Health services costs for lung cancer care in Australia: Estimates from the 45 and Up Study.
    PLoS One. 2020;15:e0238018.
    PubMed     Abstract available


  127. LIU J, Li J, Lin G, Long Z, et al
    Risk factors of lobar lymph node metastases in non-primary tumor-bearing lobes among the patients of non-small-cell lung cancer.
    PLoS One. 2020;15:e0239281.
    PubMed     Abstract available


  128. LEE JY, Fan CC, Chou NL, Lin HW, et al
    PHRF1 promotes migration and invasion by modulating ZEB1 expression.
    PLoS One. 2020;15:e0236876.
    PubMed     Abstract available


  129. SCHUZ J, Bukhtiyarov I, Olsson A, Moissonnier M, et al
    Occupational cohort study of current and former workers exposed to chrysotile in mine and processing facilities in Asbest, the Russian Federation: Cohort profile of the Asbest Chrysotile Cohort study.
    PLoS One. 2020;15:e0236475.
    PubMed     Abstract available


  130. THRONICKE A, Reinhold T, von Trott P, Grah C, et al
    Cost-effectiveness of real-world administration of chemotherapy and add-on Viscum album L. therapy compared to chemotherapy in the treatment of stage IV NSCLC patients.
    PLoS One. 2020;15:e0236426.
    PubMed     Abstract available


  131. HONG S, Youk T, Lee SJ, Kim KM, et al
    Bone metastasis and skeletal-related events in patients with solid cancer: A Korean nationwide health insurance database study.
    PLoS One. 2020;15:e0234927.
    PubMed     Abstract available


  132. TANG S, Yang M, Bai J
    Detection of pulmonary nodules based on a multiscale feature 3D U-Net convolutional neural network of transfer learning.
    PLoS One. 2020;15:e0235672.
    PubMed     Abstract available


  133. STEMMER A, Shadmi R, Bregman-Amitai O, Chettrit D, et al
    Using machine learning algorithms to review computed tomography scans and assess risk for cardiovascular disease: Retrospective analysis from the National Lung Screening Trial (NLST).
    PLoS One. 2020;15:e0236021.
    PubMed     Abstract available


  134. VIRANI NA, Kelada OJ, Kunjachan S, Detappe A, et al
    Noninvasive imaging of tumor hypoxia after nanoparticle-mediated tumor vascular disruption.
    PLoS One. 2020;15:e0236245.
    PubMed     Abstract available


  135. HUNG HY, Tseng YH, Chao HS, Chiu CH, et al
    Multidisciplinary team discussion results in survival benefit for patients with stage III non-small-cell lung cancer.
    PLoS One. 2020;15:e0236503.
    PubMed     Abstract available


  136. TU C, Pi Y, Xing S, Ling Y, et al
    Integrated analysis of long non-coding RNAs and mRNA profiles reveals potential sex-dependent biomarkers of bevacizumab/erlotinib response in advanced lung cancer.
    PLoS One. 2020;15:e0240633.
    PubMed     Abstract available


  137. LIU X, Huang G, Zhang J, Zhang L, et al
    Prognostic and clinicopathological significance of long noncoding RNA MALAT-1 expression in patients with non-small cell lung cancer: A meta-analysis.
    PLoS One. 2020;15:e0240321.
    PubMed     Abstract available


  138. SHIRE NJ, Klein AB, Golozar A, Collins JM, et al
    STK11 (LKB1) mutations in metastatic NSCLC: Prognostic value in the real world.
    PLoS One. 2020;15:e0238358.
    PubMed     Abstract available


  139. THOMAS S, Carroll JC, Brown MC, Chen Z, et al
    Nicotine dependence as a risk factor for upper aerodigestive tract (UADT) cancers: A mediation analysis.
    PLoS One. 2020;15:e0237723.
    PubMed     Abstract available


  140. GUO CY, Chou YC
    A novel machine learning strategy for model selections - Stepwise Support Vector Machine (StepSVM).
    PLoS One. 2020;15:e0238384.
    PubMed     Abstract available


  141. SAKAI A, Tagami M, Kakehashi A, Katsuyama-Yoshikawa A, et al
    Expression, intracellular localization, and mutation of EGFR in conjunctival squamous cell carcinoma and the association with prognosis and treatment.
    PLoS One. 2020;15:e0238120.
    PubMed     Abstract available


  142. CHANIAD P, Trakunran K, Geater SL, Keeratichananont W, et al
    Serum miRNAs associated with tumor-promoting cytokines in non-small cell lung cancer.
    PLoS One. 2020;15:e0241593.
    PubMed     Abstract available


  143. GU JJ, Hoj J, Rouse C, Pendergast AM, et al
    Mesenchymal stem cells promote metastasis through activation of an ABL-MMP9 signaling axis in lung cancer cells.
    PLoS One. 2020;15:e0241423.
    PubMed     Abstract available


  144. TONG J, Krieger JR, Taylor P, Bagshaw R, et al
    Cancer proteome and metabolite changes linked to SHMT2.
    PLoS One. 2020;15:e0237981.
    PubMed     Abstract available


  145. TAKADA K, Takamori S, Matsubara T, Haratake N, et al
    Clinical significance of preoperative inflammatory markers in non-small cell lung cancer patients: A multicenter retrospective study.
    PLoS One. 2020;15:e0241580.
    PubMed     Abstract available


  146. BOGNAR Z, Cseh AM, Fekete K, Antus C, et al
    Amiodarone's major metabolite, desethylamiodarone inhibits proliferation of B16-F10 melanoma cells and limits lung metastasis formation in an in vivo experimental model.
    PLoS One. 2020;15:e0239088.
    PubMed     Abstract available


  147. BANDA M, McKim KL, Myers MB, Inoue M, et al
    Outgrowth of erlotinib-resistant subpopulations recapitulated in patient-derived lung tumor spheroids and organoids.
    PLoS One. 2020;15:e0238862.
    PubMed     Abstract available


  148. CHEN B, Li H, Liu C, Xiang X, et al
    Prognostic value of the common tumour-infiltrating lymphocyte subtypes for patients with non-small cell lung cancer: A meta-analysis.
    PLoS One. 2020;15:e0242173.
    PubMed     Abstract available


  149. KOMATSU T, Chen-Yoshikawa TF, Ikeda M, Takahashi K, et al
    Impact of diabetes mellitus on postoperative outcomes in individuals with non-small-cell lung cancer: A retrospective cohort study.
    PLoS One. 2020;15:e0241930.
    PubMed     Abstract available


  150. CHANG TC, Matossian MD, Elliott S, Burks HE, et al
    Evaluation of deacetylase inhibition in metaplastic breast carcinoma using multiple derivations of preclinical models of a new patient-derived tumor.
    PLoS One. 2020;15:e0226464.
    PubMed     Abstract available


  151. NOORTMAN WA, Vriens D, Slump CH, Bussink J, et al
    Adding the temporal domain to PET radiomic features.
    PLoS One. 2020;15:e0239438.
    PubMed     Abstract available


  152. TETZLAFF F, Epping J, Golpon H, Tetzlaff J, et al
    Compression, expansion, or maybe both? Growing inequalities in lung cancer in Germany.
    PLoS One. 2020;15:e0242433.
    PubMed     Abstract available


  153. YOGO N, Hase T, Kasama T, Nishiyama K, et al
    Development of an immuno-wall device for the rapid and sensitive detection of EGFR mutations in tumor tissues resected from lung cancer patients.
    PLoS One. 2020;15:e0241422.
    PubMed     Abstract available


  154. CHEN X, Wang L, Su X, Luo SY, et al
    Identification of potential target genes and crucial pathways in small cell lung cancer based on bioinformatic strategy and human samples.
    PLoS One. 2020;15:e0242194.
    PubMed     Abstract available


  155. WANG Q, Xu L, Wang G, Chen L, et al
    Prognostic and clinicopathological significance of NRF2 expression in non-small cell lung cancer: A meta-analysis.
    PLoS One. 2020;15:e0241241.
    PubMed     Abstract available


  156. MORENO-BARBOSA F, de Celis-Alonso B, Moreno-Barbosa E, Hernandez-Lopez JM, et al
    Monte Carlo simulation of the effect of magnetic fields on brachytherapy dose distributions in lung tissue material.
    PLoS One. 2020;15:e0238704.
    PubMed     Abstract available


  157. STRATMANN JA, Lacko R, Ballo O, Shaid S, et al
    Colonization with multi-drug-resistant organisms negatively impacts survival in patients with non-small cell lung cancer.
    PLoS One. 2020;15:e0242544.
    PubMed     Abstract available


  158. KODA E, Yamashiro T, Onoe R, Handa H, et al
    CT texture analysis of mediastinal lymphadenopathy: Combining with US-based elastographic parameter and discrimination between sarcoidosis and lymph node metastasis from small cell lung cancer.
    PLoS One. 2020;15:e0243181.
    PubMed     Abstract available


  159. KIM T, Cha YJ, Park JH, Kim A, et al
    Reactive oxygen species modulator 1 expression predicts lymph node metastasis and survival in early-stage non-small cell lung cancer.
    PLoS One. 2020;15:e0239670.
    PubMed     Abstract available


  160. YU G, Shen Y, Xu X, Zhong F, et al
    Anlotinib for refractory advanced non-small-cell lung cancer: A systematic review and meta-analysis.
    PLoS One. 2020;15:e0242982.
    PubMed     Abstract available


  161. MCLAUGHLIN MF, Alam M, Smith L, Ryckman J, et al
    Stereotactic body radiation therapy mitigates radiation induced lymphopenia in early stage non-small cell lung cancer.
    PLoS One. 2020;15:e0241505.
    PubMed     Abstract available


  162. JIN J, Robeson H, Fagan P, Orloff MS, et al
    Association of PARP1-specific polymorphisms and haplotypes with non-small cell lung cancer subtypes.
    PLoS One. 2020;15:e0243509.
    PubMed     Abstract available


  163. TENDLER S, Kanter L, Lewensohn R, Ortiz-Villalon C, et al
    The prognostic implications of Notch1, Hes1, Ascl1, and DLL3 protein expression in SCLC patients receiving platinum-based chemotherapy.
    PLoS One. 2020;15:e0240973.
    PubMed     Abstract available


  164. TANG L, Chen N, He W, Zhou J, et al
    The clinicopathological features and prognosis of primary pulmonary lymphoepithelioma-like carcinoma: A systematic review and meta-analysis.
    PLoS One. 2020;15:e0240729.
    PubMed     Abstract available


  165. ERDAL BS, Demirer M, Little KJ, Amadi CC, et al
    Are quantitative features of lung nodules reproducible at different CT acquisition and reconstruction parameters?
    PLoS One. 2020;15:e0240184.
    PubMed     Abstract available


  166. NOTO FK, Sangodkar J, Adedeji BT, Moody S, et al
    The SRG rat, a Sprague-Dawley Rag2/Il2rg double-knockout validated for human tumor oncology studies.
    PLoS One. 2020;15:e0240169.
    PubMed     Abstract available


  167. LEE HS, Jung JI, Kim KH, Park SJ, et al
    Toxicodendron vernicifluum Stokes extract inhibits solid tumor growth and lung metastasis of 4T1 murine mammary carcinoma cells in BALB/c mice.
    PLoS One. 2020;15:e0241805.
    PubMed     Abstract available


  168. CHEN HJ, Tu CY, Huang KY, Chien CR, et al
    Early serum tumor marker levels after fourteen days of tyrosine kinase inhibitor targeted therapy predicts outcomes in patients with advanced lung adenocarcinoma.
    PLoS One. 2020;15:e0240736.
    PubMed     Abstract available


  169. YU H, Gu D, Qian P
    Prognostic value of ESR2 expression on adjuvant chemotherapy in completely resected NSCLC.
    PLoS One. 2020;15:e0243891.
    PubMed     Abstract available


  170. UCHIDA Y, Tsugawa T, Tanaka-Mizuno S, Noma K, et al
    Prediction of radiation pneumonitis using dose-volume histogram parameters with high attenuation in two types of cancer: A retrospective study.
    PLoS One. 2020;15:e0244143.
    PubMed     Abstract available


  171. CHEN YH, Wang TF, Chu SC, Lin CB, et al
    Incorporating radiomic feature of pretreatment 18F-FDG PET improves survival stratification in patients with EGFR-mutated lung adenocarcinoma.
    PLoS One. 2020;15:e0244502.
    PubMed     Abstract available


  172. BONERT M, Schneider M, Solyanik O, Hellbach K, et al
    Diagnostic accuracy of magnetic resonance imaging for the detection of pulmonary nodules simulated in a dedicated porcine chest phantom.
    PLoS One. 2020;15:e0244382.
    PubMed     Abstract available


  173. TOYODA Y, Tabuchi T, Hama H, Morishima T, et al
    Trends in clinical stage distribution and screening detection of cancer in Osaka, Japan: Stomach, colorectum, lung, breast and cervix.
    PLoS One. 2020;15:e0244644.
    PubMed     Abstract available


  174. GOMI T, Hara H, Watanabe Y, Mizukami S, et al
    Improved digital chest tomosynthesis image quality by use of a projection-based dual-energy virtual monochromatic convolutional neural network with super resolution.
    PLoS One. 2020;15:e0244745.
    PubMed     Abstract available


  175. WANG L, Wang W, Zeng S, Zheng H, et al
    Construction and validation of a 6-gene nomogram discriminating lung metastasis risk of breast cancer patients.
    PLoS One. 2020;15:e0244693.
    PubMed     Abstract available


    January 2019
  176. OH DK, Ji WJ, Kim WS, Choi CM, et al
    Efficacy, safety, and resistance profile of osimertinib in T790M mutation-positive non-small cell lung cancer in real-world practice.
    PLoS One. 2019;14:e0210225.
    PubMed     Abstract available


  177. CHOUAID C, Salaun M, Gounant V, Febvre M, et al
    Clinical efficacy and cost-effectiveness of endobronchial ultrasound-guided transbronchial needle aspiration for preoperative staging of non-small-cell lung cancer: Results of a French prospective multicenter trial (EVIEPEB).
    PLoS One. 2019;14:e0208992.
    PubMed     Abstract available


  178. LI Y, Appius A, Pattipaka T, Feyereislova A, et al
    Real-world management of patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in the USA.
    PLoS One. 2019;14:e0209709.
    PubMed     Abstract available


  179. SUKIENNICKI GM, Marciniak W, Muszynska M, Baszuk P, et al
    Iron levels, genes involved in iron metabolism and antioxidative processes and lung cancer incidence.
    PLoS One. 2019;14:e0208610.
    PubMed     Abstract available


  180. NISHIO M, Kubo T, Togashi K
    Estimation of lung cancer risk using homology-based emphysema quantification in patients with lung nodules.
    PLoS One. 2019;14:e0210720.
    PubMed     Abstract available


  181. AGEMI Y, Shimokawa T, Sasaki J, Miyazaki K, et al
    Prospective evaluation of the G8 screening tool for prognostication of survival in elderly patients with lung cancer: A single-institution study.
    PLoS One. 2019;14:e0210499.
    PubMed     Abstract available


  182. KIM Y, Lee D, Lee J, Lee S, et al
    Role of tumor-associated neutrophils in regulation of tumor growth in lung cancer development: A mathematical model.
    PLoS One. 2019;14:e0211041.
    PubMed     Abstract available


  183. MUENCH D, Rezzoug F, Thomas SD, Xiao J, et al
    Quadruplex-forming oligonucleotide targeted to the VEGF promoter inhibits growth of non-small cell lung cancer cells.
    PLoS One. 2019;14:e0211046.
    PubMed     Abstract available


  184. CHO YJ, Kim WS, Choi YH, Ha JY, et al
    Computerized texture analysis of pulmonary nodules in pediatric patients with osteosarcoma: Differentiation of pulmonary metastases from non-metastatic nodules.
    PLoS One. 2019;14:e0211969.
    PubMed     Abstract available


  185. KEMP JACOBSEN K, Johansen JS, Mellemgaard A, Bojesen SE, et al
    AHRR (cg05575921) methylation extent of leukocyte DNA and lung cancer survival.
    PLoS One. 2019;14:e0211745.
    PubMed     Abstract available


  186. PADAYACHEE T, Khamiakova T, Louis E, Adriaensens P, et al
    The impact of the method of extracting metabolic signal from 1H-NMR data on the classification of samples: A case study of binning and BATMAN in lung cancer.
    PLoS One. 2019;14:e0211854.
    PubMed     Abstract available


  187. SONG JH, Kim S, Lee HW, Lee YJ, et al
    Effect of intensivist involvement on clinical outcomes in patients with advanced lung cancer admitted to the intensive care unit.
    PLoS One. 2019;14:e0210951.
    PubMed     Abstract available


  188. FU JY, Wan YL, Huang TY, Wu CF, et al
    Correction: Correlation between image characteristics and pathologic findings in non small cell lung cancer patients after anatomic resection.
    PLoS One. 2019;14:e0212461.
    PubMed     Abstract available


  189. JEON SM, Kwon JW, Choi SH, Park HY, et al
    Economic burden of lung cancer: A retrospective cohort study in South Korea, 2002-2015.
    PLoS One. 2019;14:e0212878.
    PubMed     Abstract available


  190. MAGUIRE FB, Morris CR, Parikh-Patel A, Cress RD, et al
    A text-mining approach to obtain detailed treatment information from free-text fields in population-based cancer registries: A study of non-small cell lung cancer in California.
    PLoS One. 2019;14:e0212454.
    PubMed     Abstract available


  191. SCHREUDER A, Jacobs C, Gallardo-Estrella L, Prokop M, et al
    Predicting all-cause and lung cancer mortality using emphysema score progression rate between baseline and follow-up chest CT images: A comparison of risk model performances.
    PLoS One. 2019;14:e0212756.
    PubMed     Abstract available


  192. LI Y, Appius A, Pattipaka T, Feyereislova A, et al
    Correction: Real-world management of patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in the USA.
    PLoS One. 2019;14:e0212831.
    PubMed     Abstract available


  193. SISSUNG TM, Rajan A, Blumenthal GM, Liewehr DJ, et al
    Reproducibility of pharmacogenetics findings for paclitaxel in a heterogeneous population of patients with lung cancer.
    PLoS One. 2019;14:e0212097.
    PubMed     Abstract available


  194. GUO X, Liu Y, Kim JL, Kim EY, et al
    Effect of cyclical intermittent hypoxia on Ad5CMVCre induced solitary lung cancer progression and spontaneous metastases in the KrasG12D+; p53fl/fl; myristolated p110fl/fl ROSA-gfp mouse.
    PLoS One. 2019;14:e0212930.
    PubMed     Abstract available


  195. UNRINE JM, Slone SA, Sanderson W, Johnson N, et al
    A case-control study of trace-element status and lung cancer in Appalachian Kentucky.
    PLoS One. 2019;14:e0212340.
    PubMed     Abstract available


  196. CHOI YJ, Park GM, Rho JK, Kim SY, et al
    Correction: Role of IGF-Binding Protein 3 in the Resistance of EGFR Mutant Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitors.
    PLoS One. 2019;14:e0213984.
    PubMed     Abstract available



  197. Expression of Concern: Autophagosome-Mediated EGFR Down-Regulation Induced by the CK2 Inhibitor Enhances the Efficacy of EGFR-TKI on EGFR-Mutant Lung Cancer Cells with Resistance by T790M.
    PLoS One. 2019;14:e0213989.
    PubMed    


  198. STANISLAWSKA-SACHADYN A, Borzyszkowska J, Krzeminski M, Janowicz A, et al
    Folate/homocysteine metabolism and lung cancer risk among smokers.
    PLoS One. 2019;14:e0214462.
    PubMed     Abstract available


  199. GERMONPRE P, Van den Wyngaert T
    Second-line erlotinib after failure of pemetrexed-containing chemotherapy in advanced non-small cell lung cancer (NSCLC): Real-world effectiveness, safety and tolerability.
    PLoS One. 2019;14:e0215135.
    PubMed     Abstract available


  200. ZABLOCKA-SLOWINSKA K, Placzkowska S, Skorska K, Prescha A, et al
    Oxidative stress in lung cancer patients is associated with altered serum markers of lipid metabolism.
    PLoS One. 2019;14:e0215246.
    PubMed     Abstract available


  201. O'FLAHERTY L, Shnyder SD, Cooper PA, Cross SJ, et al
    Tumor growth suppression using a combination of taxol-based therapy and GSK3 inhibition in non-small cell lung cancer.
    PLoS One. 2019;14:e0214610.
    PubMed     Abstract available


  202. SHIRASAWA M, Fukui T, Kusuhara S, Harada S, et al
    Prognostic differences between oligometastatic and polymetastatic extensive disease-small cell lung cancer.
    PLoS One. 2019;14:e0214599.
    PubMed     Abstract available


  203. DUNCAN DJ, Scott M, Scorer P, Barker C, et al
    Assessment of PD-L1 mRNA and protein expression in non-small cell lung cancer, head and neck squamous cell carcinoma and urothelial carcinoma tissue specimens using RNAScope and immunohistochemistry.
    PLoS One. 2019;14:e0215393.
    PubMed     Abstract available


  204. YUN PJ, Wang GC, Chen YY, Wu TH, et al
    Brain metastases in resected non-small cell lung cancer: The impact of different tyrosine kinase inhibitors.
    PLoS One. 2019;14:e0215923.
    PubMed     Abstract available


  205. HU ZG, Hu K, Li WX, Zeng FJ, et al
    Prognostic factors and nomogram for cancer-specific death in non small cell lung cancer with malignant pericardial effusion.
    PLoS One. 2019;14:e0217007.
    PubMed     Abstract available


  206. STANZE H, Schneider N, Nauck F, Marx G, et al
    "I can't get it into my head that I have cancer..."-A qualitative interview study on needs of patients with lung cancer.
    PLoS One. 2019;14:e0216778.
    PubMed     Abstract available


  207. SUZUKI A, Puri S, Leland P, Puri A, et al
    Subcellular compartmentalization of PKM2 identifies anti-PKM2 therapy response in vitro and in vivo mouse model of human non-small-cell lung cancer.
    PLoS One. 2019;14:e0217131.
    PubMed     Abstract available


  208. THEELEN WSME, Kuilman T, Schulze K, Zou W, et al
    Absence of PD-L1 expression on tumor cells in the context of an activated immune infiltrate may indicate impaired IFNgamma signaling in non-small cell lung cancer.
    PLoS One. 2019;14:e0216864.
    PubMed     Abstract available


  209. LIU J, Liu S, Deng X, Rao J, et al
    MicroRNA-582-5p suppresses non-small cell lung cancer cells growth and invasion via downregulating NOTCH1.
    PLoS One. 2019;14:e0217652.
    PubMed     Abstract available


  210. NAKAMURA H, Fujii K, Gupta V, Hata H, et al
    Identification of key modules and hub genes for small-cell lung carcinoma and large-cell neuroendocrine lung carcinoma by weighted gene co-expression network analysis of clinical tissue-proteomes.
    PLoS One. 2019;14:e0217105.
    PubMed     Abstract available


  211. RICE SJ, Liu X, Wang HG, Belani CP, et al
    EGFR mutations and AKT phosphorylation are markers for sensitivity to combined MCL-1 and BCL-2/xL inhibition in non-small cell lung cancer.
    PLoS One. 2019;14:e0217657.
    PubMed     Abstract available


  212. BYCHKOV M, Shenkarev Z, Shulepko M, Shlepova O, et al
    Water-soluble variant of human Lynx1 induces cell cycle arrest and apoptosis in lung cancer cells via modulation of alpha7 nicotinic acetylcholine receptors.
    PLoS One. 2019;14:e0217339.
    PubMed     Abstract available


  213. WALTER J, Tufman A, Holle R, Schwarzkopf L, et al
    "Age matters"-German claims data indicate disparities in lung cancer care between elderly and young patients.
    PLoS One. 2019;14:e0217434.
    PubMed     Abstract available


  214. NAM MW, Kim JM, Cheong JH, Ryu JI, et al
    Paradoxical relationship between body mass index and bone mineral density in patients with non-small cell lung cancer with brain metastasis.
    PLoS One. 2019;14:e0218825.
    PubMed     Abstract available


  215. BEHRENDT CE, Cosgrove CM, Johnson NJ, Altekruse SF, et al
    Are associations between psychosocial stressors and incident lung cancer attributable to smoking?
    PLoS One. 2019;14:e0218439.
    PubMed     Abstract available


  216. LEE CC, Soon YY, Tan CL, Koh WY, et al
    Discordance of epidermal growth factor receptor mutation between primary lung tumor and paired distant metastases in non-small cell lung cancer: A systematic review and meta-analysis.
    PLoS One. 2019;14:e0218414.
    PubMed     Abstract available


  217. ALCANTUD JCR, Varela G, Santos-Buitrago B, Santos-Garcia G, et al
    Analysis of survival for lung cancer resections cases with fuzzy and soft set theory in surgical decision making.
    PLoS One. 2019;14:e0218283.
    PubMed     Abstract available


  218. RADKIEWICZ C, Dickman PW, Johansson ALV, Wagenius G, et al
    Sex and survival in non-small cell lung cancer: A nationwide cohort study.
    PLoS One. 2019;14:e0219206.
    PubMed     Abstract available


  219. DACOSTA-NOBLE P, Costantini A, Dumenil C, Dumoulin J, et al
    Positive plasma cotinine during platinum-based chemotherapy is associated with poor response rate in advanced non-small cell lung cancer patients.
    PLoS One. 2019;14:e0219080.
    PubMed     Abstract available


  220. POVSIC M, Enstone A, Wyn R, Kornalska K, et al
    Real-world effectiveness and tolerability of small-cell lung cancer (SCLC) treatments: A systematic literature review (SLR).
    PLoS One. 2019;14:e0219622.
    PubMed     Abstract available


  221. GONZALEZ J, Henschke CI, Yankelevitz DF, Seijo LM, et al
    Emphysema phenotypes and lung cancer risk.
    PLoS One. 2019;14:e0219187.
    PubMed     Abstract available


  222. WEI T, Zhu D, Yang Y, Yuan G, et al
    The application of nano-enrichment in CTC detection and the clinical significance of CTCs in non-small cell lung cancer (NSCLC) treatment.
    PLoS One. 2019;14:e0219129.
    PubMed     Abstract available


  223. CAMERLINGO R, Miceli R, Marra L, Rea G, et al
    Conditioned medium of primary lung cancer cells induces EMT in A549 lung cancer cell line by TGF-ss1 and miRNA21 cooperation.
    PLoS One. 2019;14:e0219597.
    PubMed     Abstract available


  224. TOPKAN E, Ozdemir Y, Kucuk A, Besen AA, et al
    Significance of overall concurrent chemoradiotherapy duration on survival outcomes of stage IIIB/C non-small-cell lung carcinoma patients: Analysis of 956 patients.
    PLoS One. 2019;14:e0218627.
    PubMed     Abstract available


  225. LUNG J, Hung MS, Lin YC, Lee KF, et al
    MET exon 14 skipping mutations and gene amplification in a Taiwanese lung cancer population.
    PLoS One. 2019;14:e0220670.
    PubMed     Abstract available


  226. EDAHIRO R, Kanazu M, Kurebe H, Mori M, et al
    Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan.
    PLoS One. 2019;14:e0220570.
    PubMed     Abstract available


  227. CHEN Y, Watson TR, Criss SD, Eckel A, et al
    A simulation study of the effect of lung cancer screening in China, Japan, Singapore, and South Korea.
    PLoS One. 2019;14:e0220610.
    PubMed     Abstract available


  228. DONG J, Zhu D, Tang X, Lu D, et al
    Circulating tumor cells in pulmonary vein and peripheral arterial provide a metric for PD-L1 diagnosis and prognosis of patients with non-small cell lung cancer.
    PLoS One. 2019;14:e0220306.
    PubMed     Abstract available


  229. PIPER AJ, Clark JL, Mercado-Matos J, Matthew-Onabanjo AN, et al
    Insulin Receptor Substrate-1 (IRS-1) and IRS-2 expression levels are associated with prognosis in non-small cell lung cancer (NSCLC).
    PLoS One. 2019;14:e0220567.
    PubMed     Abstract available


  230. KOYAMA N, Iwai Y, Nagai Y, Aoshiba K, et al
    Idiopathic pulmonary fibrosis in small cell lung cancer as a predictive factor for poor clinical outcome and risk of its exacerbation.
    PLoS One. 2019;14:e0221718.
    PubMed     Abstract available


  231. PUJOL JL, Coffy A, Camerini A, Kotsakis A, et al
    An individual patient-data meta-analysis of metronomic oral vinorelbine in metastatic non-small cell lung cancer.
    PLoS One. 2019;14:e0220988.
    PubMed     Abstract available


  232. YU S, Choi HH, Kim IW, Kim TJ, et al
    Conditioned medium from asbestos-exposed fibroblasts affects proliferation and invasion of lung cancer cell lines.
    PLoS One. 2019;14:e0222160.
    PubMed     Abstract available


  233. PAIK SH, Yeo CD, Jeong JE, Kim JS, et al
    Prevalence and analysis of tobacco use disorder in patients diagnosed with lung cancer.
    PLoS One. 2019;14:e0220127.
    PubMed     Abstract available


  234. KUNIMASA K, Kato K, Imamura F, Kukita Y, et al
    Quantitative detection of ALK fusion breakpoints in plasma cell-free DNA from patients with non-small cell lung cancer using PCR-based target sequencing with a tiling primer set and two-step mapping/alignment.
    PLoS One. 2019;14:e0222233.
    PubMed     Abstract available


  235. CHILET-ROSELL E, Parker LA, Hernandez-Aguado I, Pastor-Valero M, et al
    The determinants of lung cancer after detecting a solitary pulmonary nodule are different in men and women, for both chest radiograph and CT.
    PLoS One. 2019;14:e0221134.
    PubMed     Abstract available


  236. BANSAL M, He J, Peyton M, Kustagi M, et al
    Elucidating synergistic dependencies in lung adenocarcinoma by proteome-wide signaling-network analysis.
    PLoS One. 2019;14:e0208646.
    PubMed     Abstract available


  237. HU HP, Chan H, Ujiie H, Bernards N, et al
    Nanoparticle-based CT visualization of pulmonary vasculature for minimally-invasive thoracic surgery planning.
    PLoS One. 2019;14:e0209501.
    PubMed     Abstract available


  238. ZHANG H, Chen J, Liu T, Dang J, et al
    First-line treatments in EGFR-mutated advanced non-small cell lung cancer: A network meta-analysis.
    PLoS One. 2019;14:e0223530.
    PubMed     Abstract available


  239. HUA X, Han SH, Wei SZ, Wu Y, et al
    Clinical features of pulmonary embolism in patients with lung cancer: A meta-analysis.
    PLoS One. 2019;14:e0223230.
    PubMed     Abstract available


  240. SHAO B, Bjaanaes MM, Helland A, Schutte C, et al
    EMT network-based feature selection improves prognosis prediction in lung adenocarcinoma.
    PLoS One. 2019;14:e0204186.
    PubMed     Abstract available


  241. MITSUYA K, Nakasu Y, Hayashi N, Deguchi S, et al
    Palliative cerebrospinal fluid shunting for leptomeningeal metastasis-related hydrocephalus in patients with lung adenocarcinoma: A single-center retrospective study.
    PLoS One. 2019;14:e0210074.
    PubMed     Abstract available


  242. LU S, Dong Z
    Additive effects of a small molecular PCNA inhibitor PCNA-I1S and DNA damaging agents on growth inhibition and DNA damage in prostate and lung cancer cells.
    PLoS One. 2019;14:e0223894.
    PubMed     Abstract available


  243. CIERESZKO A, Dietrich MA, Slowinska M, Nynca J, et al
    Identification of protein changes in the blood plasma of lung cancer patients subjected to chemotherapy using a 2D-DIGE approach.
    PLoS One. 2019;14:e0223840.
    PubMed     Abstract available


  244. DUNCAN DJ, Vandenberghe ME, Scott MLJ, Barker C, et al
    Fast fluorescence in situ hybridisation for the enhanced detection of MET in non-small cell lung cancer.
    PLoS One. 2019;14:e0223926.
    PubMed     Abstract available


  245. ZHANG P, He D, Song E, Jiang M, et al
    Celecoxib enhances the sensitivity of non-small-cell lung cancer cells to radiation-induced apoptosis through downregulation of the Akt/mTOR signaling pathway and COX-2 expression.
    PLoS One. 2019;14:e0223760.
    PubMed     Abstract available


  246. GANEM J, Thureau S, Gouel P, Dubray B, et al
    Prognostic value of post-induction chemotherapy 18F-FDG PET-CT in stage II/III non-small cell lung cancer before (chemo-) radiation.
    PLoS One. 2019;14:e0222885.
    PubMed     Abstract available


  247. PARK CH, Kim TH, Lee S, Moon DH, et al
    Correlation between maximal tumor diameter of fresh pathology specimens and computed tomography images in lung adenocarcinoma.
    PLoS One. 2019;14:e0211141.
    PubMed     Abstract available


  248. GU Y, Lu X, Zhang B, Zhao Y, et al
    Automatic lung nodule detection using multi-scale dot nodule-enhancement filter and weighted support vector machines in chest computed tomography.
    PLoS One. 2019;14:e0210551.
    PubMed     Abstract available



  249. Correction: Celecoxib enhances the sensitivity of non-small-cell lung cancer cells to radiation-induced apoptosis through downregulation of the Akt/mTOR signaling pathway and COX-2 expression.
    PLoS One. 2019;14:e0224843.
    PubMed     Abstract available


  250. SUZUKI H, Oishi H, Noda M, Watanabe T, et al
    Correlation between the native lung volume change and postoperative pulmonary function after single lung transplantation for lymphangioleiomyomatosis: Evaluation of lung volume by three-dimensional computed tomography volumetry.
    PLoS One. 2019;14:e0210975.
    PubMed     Abstract available


  251. VARBANOV HP, Kuttler F, Banfi D, Turcatti G, et al
    Screening-based approach to discover effective platinum-based chemotherapies for cancers with poor prognosis.
    PLoS One. 2019;14:e0211268.
    PubMed     Abstract available


  252. WU Z, Zhang X, He Z, Hou L, et al
    Identifying candidate diagnostic markers for early stage of non-small cell lung cancer.
    PLoS One. 2019;14:e0225080.
    PubMed     Abstract available


  253. BRUNI A, Giaj-Levra N, Ciammella P, Maragna V, et al
    Management of locally advanced non-small cell lung cancer in the modern era: A national Italian survey on diagnosis, treatment and multidisciplinary approach.
    PLoS One. 2019;14:e0224027.
    PubMed     Abstract available


  254. GOMES AL, Kinchesh P, Gilchrist S, Allen PD, et al
    Cardio-Respiratory synchronized bSSFP MRI for high throughput in vivo lung tumour quantification.
    PLoS One. 2019;14:e0212172.
    PubMed     Abstract available


  255. HAYASHI K, Motoishi M, Sawai S, Horimoto K, et al
    Postoperative delirium after lung resection for primary lung cancer: Risk factors, risk scoring system, and prognosis.
    PLoS One. 2019;14:e0223917.
    PubMed     Abstract available


  256. KIM I, Eom JS, Kim AR, Lee CH, et al
    Molecular analysis of small tissue samples obtained via transbronchial lung biopsy using radial probe endobronchial ultrasound.
    PLoS One. 2019;14:e0212672.
    PubMed     Abstract available


  257. MINCHOM A, Mak D, Gunapala R, Walder D, et al
    A prospective observational study of on-treatment plasma homocysteine levels as a biomarker of toxicity, depression and vitamin supplementation lead-in time pre pemetrexed, in patients with non-small cell lung cancer and malignant mesothelioma.
    PLoS One. 2019;14:e0225509.
    PubMed     Abstract available


  258. ZHAO JG, Wang JF, Feng JF, Jin XY, et al
    HHIP overexpression inhibits the proliferation, migration and invasion of non-small cell lung cancer.
    PLoS One. 2019;14:e0225755.
    PubMed     Abstract available


  259. PO JW, Ma Y, Balakrishna B, Brungs D, et al
    Immunomagnetic isolation of circulating melanoma cells and detection of PD-L1 status.
    PLoS One. 2019;14:e0211866.
    PubMed     Abstract available


  260. TRAN LS, Pham HT, Tran VU, Tran TT, et al
    Ultra-deep massively parallel sequencing with unique molecular identifier tagging achieves comparable performance to droplet digital PCR for detection and quantification of circulating tumor DNA from lung cancer patients.
    PLoS One. 2019;14:e0226193.
    PubMed     Abstract available


  261. SHIINA Y, Nakajima T, Yamamoto T, Tanaka K, et al
    The D-dimer level predicts the postoperative prognosis in patients with non-small cell lung cancer.
    PLoS One. 2019;14:e0222050.
    PubMed     Abstract available


  262. DANILOV SM, Metzger R, Klieser E, Sotlar K, et al
    Tissue ACE phenotyping in lung cancer.
    PLoS One. 2019;14:e0226553.
    PubMed     Abstract available


  263. LEE SY, Walter V, Zhu J, Salzberg AC, et al
    Impact of HFE variants and sex in lung cancer.
    PLoS One. 2019;14:e0226821.
    PubMed     Abstract available


  264. BODEN S, Myte R, Wennberg M, Harlid S, et al
    The inflammatory potential of diet in determining cancer risk; A prospective investigation of two dietary pattern scores.
    PLoS One. 2019;14:e0214551.
    PubMed     Abstract available


  265. BLOCKER SJ, Mowery YM, Holbrook MD, Qi Y, et al
    Bridging the translational gap: Implementation of multimodal small animal imaging strategies for tumor burden assessment in a co-clinical trial.
    PLoS One. 2019;14:e0207555.
    PubMed     Abstract available


  266. GU Y, Cheng Y, Song Y, Zhang Z, et al
    Retraction: MicroRNA-493 Suppresses Tumor Growth, Invasion and Metastasis of Lung cancer by Regulating E2F1.
    PLoS One. 2019;14:e0227503.
    PubMed    


  267. MATSUBARA T, Toyokawa G, Takada K, Kinoshita F, et al
    The association and prognostic impact of enhancer of zeste homologue 2 expression and epithelial-mesenchymal transition in resected lung adenocarcinoma.
    PLoS One. 2019;14:e0215103.
    PubMed     Abstract available


  268. DU Q, Baine M, Bavitz K, McAllister J, et al
    Radiomic feature stability across 4D respiratory phases and its impact on lung tumor prognosis prediction.
    PLoS One. 2019;14:e0216480.
    PubMed     Abstract available


  269. TVEITARAS MK, Selheim F, Sortland K, Reed RK, et al
    Protein expression profiling of plasma and lungs at different stages of metastatic development in a human triple negative breast cancer xenograft model.
    PLoS One. 2019;14:e0215909.
    PubMed     Abstract available


  270. ZHAO Z, Wu W, Duan X, Zeng G, et al
    The value of cytoreductive nephrectomy on the survival of metastatic renal carcinoma patients based on the number of site-specific metastases.
    PLoS One. 2019;14:e0215861.
    PubMed     Abstract available


  271. KURIAKOSE AE, Hu W, Nguyen KT, Menon JU, et al
    Scaffold-based lung tumor culture on porous PLGA microparticle substrates.
    PLoS One. 2019;14:e0217640.
    PubMed     Abstract available


  272. YAMAUCHI I, Yasoda A, Matsumoto S, Sakamori Y, et al
    Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab.
    PLoS One. 2019;14:e0216954.
    PubMed     Abstract available


  273. ABARIUTE L, Lard M, Hebisch E, Prinz CN, et al
    Uptake of nanowires by human lung adenocarcinoma cells.
    PLoS One. 2019;14:e0218122.
    PubMed     Abstract available


  274. RABIN-COURT A, Rodrigues MR, Zhang XM, Perry RJ, et al
    Obesity-associated, but not obesity-independent, tumors respond to insulin by increasing mitochondrial glucose oxidation.
    PLoS One. 2019;14:e0218126.
    PubMed     Abstract available


  275. TAKADA K, Shimokawa M, Tanaka K, Kohashi K, et al
    Association between peripheral blood markers and immune-related factors on tumor cells in patients with resected primary lung adenocarcinoma.
    PLoS One. 2019;14:e0217991.
    PubMed     Abstract available


  276. PARK KR, Yun JS, Park MH, Jung YY, et al
    Loss of parkin reduces lung tumor development by blocking p21 degradation.
    PLoS One. 2019;14:e0217037.
    PubMed     Abstract available


  277. BERENT TE, Dorschner JM, Meyer T, Craig TA, et al
    Impaired cardiac performance, protein synthesis, and mitochondrial function in tumor-bearing mice.
    PLoS One. 2019;14:e0226440.
    PubMed     Abstract available


  278. CHUN YJ, Choi JW, Hong MH, Jung D, et al
    Molecular characterization of lung adenocarcinoma from Korean patients using next generation sequencing.
    PLoS One. 2019;14:e0224379.
    PubMed     Abstract available


  279. TANAKA T, Akiyoshi H, Nishida H, Mie K, et al
    Contrast-enhanced computed tomography findings of canine primary renal tumors including renal cell carcinoma, lymphoma, and hemangiosarcoma.
    PLoS One. 2019;14:e0225211.
    PubMed     Abstract available


  280. KIM A, Lee SJ, Ahn J, Park WY, et al
    The prognostic significance of tumor-infiltrating lymphocytes assessment with hematoxylin and eosin sections in resected primary lung adenocarcinoma.
    PLoS One. 2019;14:e0224430.
    PubMed     Abstract available


  281. MOON DH, Park CH, Kang DY, Lee HS, et al
    Significance of the lobe-specific emphysema index to predict prolonged air leak after anatomical segmentectomy.
    PLoS One. 2019;14:e0224519.
    PubMed     Abstract available


  282. CHOI W, Kim SH, Kang SH, Park JJ, et al
    Differential impact of smoking on cardiac or non-cardiac death according to age.
    PLoS One. 2019;14:e0224486.
    PubMed     Abstract available


  283. VINCENTEN JPL, van Essen HF, Lissenberg-Witte BI, Bulkmans NWJ, et al
    Clonality analysis of pulmonary tumors by genome-wide copy number profiling.
    PLoS One. 2019;14:e0223827.
    PubMed     Abstract available


  284. GU K, Lee HY, Lee K, Choi JY, et al
    Integrated evaluation of clinical, pathological and radiological prognostic factors in squamous cell carcinoma of the lung.
    PLoS One. 2019;14:e0223298.
    PubMed     Abstract available


  285. HE Y, Liu H, Wang S, Chen Y, et al
    Prognostic nomogram predicts overall survival in pulmonary large cell neuroendocrine carcinoma.
    PLoS One. 2019;14:e0223275.
    PubMed     Abstract available


  286. TAMIRAT MZ, Koivu M, Elenius K, Johnson MS, et al
    Structural characterization of EGFR exon 19 deletion mutation using molecular dynamics simulation.
    PLoS One. 2019;14:e0222814.
    PubMed     Abstract available


  287. GER RB, Meier JG, Pahlka RB, Gay S, et al
    Effects of alterations in positron emission tomography imaging parameters on radiomics features.
    PLoS One. 2019;14:e0221877.
    PubMed     Abstract available


  288. RAI SN, Srivastava S, Pan J, Wu X, et al
    Multi-group diagnostic classification of high-dimensional data using differential scanning calorimetry plasma thermograms.
    PLoS One. 2019;14:e0220765.
    PubMed     Abstract available


  289. MARSHALL EA, Stewart GL, Sage AP, Lam WL, et al
    Beyond sequence homology: Cellular biology limits the potential of XIST to act as a miRNA sponge.
    PLoS One. 2019;14:e0221371.
    PubMed     Abstract available


  290. CHEN HC, Tan EC, Liao CH, Lin ZZ, et al
    Development and validation of nomograms for predicting survival probability of patients with advanced adenocarcinoma in different EGFR mutation status.
    PLoS One. 2019;14:e0220730.
    PubMed     Abstract available


    January 2018
  291. CHEN WC, Su VY, Yu WK, Chen YW, et al
    Prognostic factors of noninvasive mechanical ventilation in lung cancer patients with acute respiratory failure.
    PLoS One. 2018;13:e0191204.
    PubMed     Abstract available



  292. Correction: Risk of thromboembolism in cisplatin versus carboplatin-treated patients with lung cancer.
    PLoS One. 2018;13:e0191454.
    PubMed     Abstract available


  293. CHUANG MC, Yang YH, Tsai YH, Hsieh MJ, et al
    Survival benefit associated with metformin use in inoperable non-small cell lung cancer patients with diabetes: A population-based retrospective cohort study.
    PLoS One. 2018;13:e0191129.
    PubMed     Abstract available


  294. BELQAID K, Tishelman C, Orrevall Y, Mansson-Brahme E, et al
    Dealing with taste and smell alterations-A qualitative interview study of people treated for lung cancer.
    PLoS One. 2018;13:e0191117.
    PubMed     Abstract available


  295. PARK S, Ha S, Lee SH, Paeng JC, et al
    Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor.
    PLoS One. 2018;13:e0189766.
    PubMed     Abstract available


  296. SHIN DW, Chun S, Kim YI, Kim SJ, et al
    A national survey of lung cancer specialists' views on low-dose CT screening for lung cancer in Korea.
    PLoS One. 2018;13:e0192626.
    PubMed     Abstract available


  297. KILVAER TK, Rakaee M, Hellevik T, Ostman A, et al
    Tissue analyses reveal a potential immune-adjuvant function of FAP-1 positive fibroblasts in non-small cell lung cancer.
    PLoS One. 2018;13:e0192157.
    PubMed     Abstract available


  298. KIRIU T, Yamamoto M, Nagano T, Hazama D, et al
    The time-series behavior of neutrophil-to-lymphocyte ratio is useful as a predictive marker in non-small cell lung cancer.
    PLoS One. 2018;13:e0193018.
    PubMed     Abstract available


  299. HOVANEC J, Siemiatycki J, Conway DI, Olsson A, et al
    Lung cancer and socioeconomic status in a pooled analysis of case-control studies.
    PLoS One. 2018;13:e0192999.
    PubMed     Abstract available


  300. PAK K, Kim K, Kim MH, Eom JS, et al
    A decision tree model for predicting mediastinal lymph node metastasis in non-small cell lung cancer with F-18 FDG PET/CT.
    PLoS One. 2018;13:e0193403.
    PubMed     Abstract available


  301. TAMIYA M, Tamiya A, Inoue T, Kimura M, et al
    Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer: A retrospective multicenter trial.
    PLoS One. 2018;13:e0192227.
    PubMed     Abstract available



  302. Correction: Modulation of Pathways Underlying Distinct Cell Death Mechanisms in Two Human Lung Cancer Cell Lines in Response to SN1 Methylating Agents Treatment.
    PLoS One. 2018;13:e0194257.
    PubMed     Abstract available


  303. CARVALHO S, Leijenaar RTH, Troost EGC, van Timmeren JE, et al
    18F-fluorodeoxyglucose positron-emission tomography (FDG-PET)-Radiomics of metastatic lymph nodes and primary tumor in non-small cell lung cancer (NSCLC) - A prospective externally validated study.
    PLoS One. 2018;13:e0192859.
    PubMed     Abstract available


  304. MALEKI VAREKI S, Salim KY, Danter WR, Koropatnick J, et al
    Novel anti-cancer drug COTI-2 synergizes with therapeutic agents and does not induce resistance or exhibit cross-resistance in human cancer cell lines.
    PLoS One. 2018;13:e0191766.
    PubMed     Abstract available


  305. HAN Y, Kim HJ, Kong KA, Kim SJ, et al
    Diagnosis of small pulmonary lesions by transbronchial lung biopsy with radial endobronchial ultrasound and virtual bronchoscopic navigation versus CT-guided transthoracic needle biopsy: A systematic review and meta-analysis.
    PLoS One. 2018;13:e0191590.
    PubMed     Abstract available


  306. ZHANG Z, Wang H, Ding Q, Xing Y, et al
    Establishment of patient-derived tumor spheroids for non-small cell lung cancer.
    PLoS One. 2018;13:e0194016.
    PubMed     Abstract available


  307. MIHOUB M, Pichette A, Sylla B, Gauthier C, et al
    Bidesmosidic betulin saponin bearing L-rhamnopyranoside moieties induces apoptosis and inhibition of lung cancer cells growth in vitro and in vivo.
    PLoS One. 2018;13:e0193386.
    PubMed     Abstract available


  308. BUHL IK, Santoni-Rugiu E, Ravn J, Hansen A, et al
    Molecular prediction of adjuvant cisplatin efficacy in Non-Small Cell Lung Cancer (NSCLC)-validation in two independent cohorts.
    PLoS One. 2018;13:e0194609.
    PubMed     Abstract available


  309. DEHUA Z, Mingming C, Jisheng W
    Meta-analysis of gemcitabine in brief versus prolonged low-dose infusion for advanced non-small cell lung cancer.
    PLoS One. 2018;13:e0193814.
    PubMed     Abstract available


  310. CHANG WY, Wu YL, Su PL, Yang SC, et al
    The impact of EGFR mutations on the incidence and survival of stages I to III NSCLC patients with subsequent brain metastasis.
    PLoS One. 2018;13:e0192161.
    PubMed     Abstract available


  311. KIM CR, Kim EY, Kim YS, Ahn HK, et al
    Histologic subtypes are not associated with the presence of sarcopenia in lung cancer.
    PLoS One. 2018;13:e0194626.
    PubMed     Abstract available


  312. CHEN CH, Chang CK, Tu CY, Liao WC, et al
    Radiomic features analysis in computed tomography images of lung nodule classification.
    PLoS One. 2018;13:e0192002.
    PubMed     Abstract available


  313. FU M, Travier N, Martin-Sanchez JC, Martinez-Sanchez JM, et al
    Identifying high-risk individuals for lung cancer screening: Going beyond NLST criteria.
    PLoS One. 2018;13:e0195441.
    PubMed     Abstract available


  314. LEE EH, Park CH, Choi HJ, Kawala RA, et al
    Dexamethasone modified by gamma-irradiation as a novel anticancer drug in human non-small cell lung cancer.
    PLoS One. 2018;13:e0194341.
    PubMed     Abstract available


  315. ERNST AK, Putscher A, Samatov TR, Suling A, et al
    Knockdown of L1CAM significantly reduces metastasis in a xenograft model of human melanoma: L1CAM is a potential target for anti-melanoma therapy.
    PLoS One. 2018;13:e0192525.
    PubMed     Abstract available


  316. LIU K, Zheng D, Xu G, Du Z, et al
    Correction: Local thoracic therapy improve prognosis for stage IV non-small cell lung cancer patients combined with chemotherapy: A Surveillance, Epidemiology, and End Results database analysis.
    PLoS One. 2018;13:e0196618.
    PubMed     Abstract available


  317. BISAGNI A, Pagano M, Maramotti S, Zanelli F, et al
    Higher expression of miR-133b is associated with better efficacy of erlotinib as the second or third line in non-small cell lung cancer patients.
    PLoS One. 2018;13:e0196350.
    PubMed     Abstract available


  318. CIRCU M, Cardelli J, Barr MP, O'Byrne K, et al
    Correction: Modulating lysosomal function through lysosome membrane permeabilization or autophagy suppression restores sensitivity to cisplatin in refractory non-small-cell lung cancer cells.
    PLoS One. 2018;13:e0197016.
    PubMed     Abstract available


  319. DEROUEN MC, Hu L, McKinley M, Gali K, et al
    Incidence of lung cancer histologic cell-types according to neighborhood factors: A population based study in California.
    PLoS One. 2018;13:e0197146.
    PubMed     Abstract available


  320. EDELSBERG J, Weycker D, Atwood M, Hamilton-Fairley G, et al
    Cost-effectiveness of an autoantibody test (EarlyCDT-Lung) as an aid to early diagnosis of lung cancer in patients with incidentally detected pulmonary nodules.
    PLoS One. 2018;13:e0197826.
    PubMed     Abstract available


  321. KIM H, Kwon HJ, Park SY, Park Y, et al
    Clinicopathological analysis and prognostic significance of programmed cell death-ligand 1 protein and mRNA expression in non-small cell lung cancer.
    PLoS One. 2018;13:e0198634.
    PubMed     Abstract available


  322. ZHANG X, Nakajima T, Kim M, Yamaguchi A, et al
    Activatable fluorescence detection of epidermal growth factor receptor positive mediastinal lymph nodes in murine lung cancer model.
    PLoS One. 2018;13:e0198224.
    PubMed     Abstract available


  323. WALTER RFH, Rozynek P, Casjens S, Werner R, et al
    Methylation of L1RE1, RARB, and RASSF1 function as possible biomarkers for the differential diagnosis of lung cancer.
    PLoS One. 2018;13:e0195716.
    PubMed     Abstract available


  324. KIM KI, Jun JH, Baek H, Kim JH, et al
    Oral administration of herbal medicines for radiation pneumonitis in lung cancer patients: A systematic review and meta-analysis.
    PLoS One. 2018;13:e0198015.
    PubMed     Abstract available


  325. GU L, Wang Z, Zuo J, Li H, et al
    Prognostic significance of NF-kappaB expression in non-small cell lung cancer: A meta-analysis.
    PLoS One. 2018;13:e0198223.
    PubMed     Abstract available


  326. CHORNER PM, Moorehead RA
    A-674563, a putative AKT1 inhibitor that also suppresses CDK2 activity, inhibits human NSCLC cell growth more effectively than the pan-AKT inhibitor, MK-2206.
    PLoS One. 2018;13:e0193344.
    PubMed     Abstract available


  327. SILVA MA, Ryall KA, Wilm C, Caldara J, et al
    PD-L1 immunostaining scoring for non-small cell lung cancer based on immunosurveillance parameters.
    PLoS One. 2018;13:e0196464.
    PubMed     Abstract available


  328. HSIEH LY, Chou FJ, Guo SE
    Information needs of patients with lung cancer from diagnosis until first treatment follow-up.
    PLoS One. 2018;13:e0199515.
    PubMed     Abstract available


  329. DANISH L, Imig D, Allgower F, Scheurich P, et al
    Bcl-2-mediated control of TRAIL-induced apoptotic response in the non-small lung cancer cell line NCI-H460 is effective at late caspase processing steps.
    PLoS One. 2018;13:e0198203.
    PubMed     Abstract available


  330. BLUME JD, D'Agostino McGowan L, Dupont WD, Greevy RA Jr, et al
    Second-generation p-values: Improved rigor, reproducibility, & transparency in statistical analyses.
    PLoS One. 2018;13:e0188299.
    PubMed     Abstract available


  331. PLAGNOL V, Woodhouse S, Howarth K, Lensing S, et al
    Analytical validation of a next generation sequencing liquid biopsy assay for high sensitivity broad molecular profiling.
    PLoS One. 2018;13:e0193802.
    PubMed     Abstract available


  332. YANG M, Feng Y, Yue C, Xu B, et al
    Lower expression level of IL-33 is associated with poor prognosis of pulmonary adenocarcinoma.
    PLoS One. 2018;13:e0193428.
    PubMed     Abstract available


  333. FERRARINI A, Forcato C, Buson G, Tononi P, et al
    A streamlined workflow for single-cells genome-wide copy-number profiling by low-pass sequencing of LM-PCR whole-genome amplification products.
    PLoS One. 2018;13:e0193689.
    PubMed     Abstract available


  334. ROTH JA, Carter-Harris L, Brandzel S, Buist DSM, et al
    A qualitative study exploring patient motivations for screening for lung cancer.
    PLoS One. 2018;13:e0196758.
    PubMed     Abstract available


  335. HEIDEN BT, Chen G, Hermann M, Brown RKJ, et al
    18F-FDG PET intensity correlates with a hypoxic gene signature and other oncogenic abnormalities in operable non-small cell lung cancer.
    PLoS One. 2018;13:e0199970.
    PubMed     Abstract available


  336. LIM JU, Yeo CD, Kang HS, Park CK, et al
    Prognostic value of platelet count and lymphocyte to monocyte ratio combination in stage IV non-small cell lung cancer with malignant pleural effusion.
    PLoS One. 2018;13:e0200341.
    PubMed     Abstract available


  337. DUAN L, Ye L, Zhuang L, Zou X, et al
    VEGFC/VEGFR3 axis mediates TGFbeta1-induced epithelial-to-mesenchymal transition in non-small cell lung cancer cells.
    PLoS One. 2018;13:e0200452.
    PubMed     Abstract available


  338. LU X, Gao J, Zhang Y, Zhao T, et al
    CTEN induces epithelial-mesenchymal transition (EMT) and metastasis in non small cell lung cancer cells.
    PLoS One. 2018;13:e0198823.
    PubMed     Abstract available


  339. PANNUTI A, Filipovic A, Hicks C, Lefkowitz E, et al
    Novel putative drivers revealed by targeted exome sequencing of advanced solid tumors.
    PLoS One. 2018;13:e0194790.
    PubMed     Abstract available


  340. YURCHENKO KS, Zhou P, Kovner AV, Zavjalov EL, et al
    Oncolytic effect of wild-type Newcastle disease virus isolates in cancer cell lines in vitro and in vivo on xenograft model.
    PLoS One. 2018;13:e0195425.
    PubMed     Abstract available


  341. FATHI Z, Mousavi SAJ, Roudi R, Ghazi F, et al
    Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients.
    PLoS One. 2018;13:e0200633.
    PubMed     Abstract available


  342. ARMOIRY X, Tsertsvadze A, Connock M, Royle P, et al
    Comparative efficacy and safety of licensed treatments for previously treated non-small cell lung cancer: A systematic review and network meta-analysis.
    PLoS One. 2018;13:e0199575.
    PubMed     Abstract available


  343. DUMENIL C, Massiani MA, Dumoulin J, Giraud V, et al
    Clinical factors associated with early progression and grade 3-4 toxicity in patients with advanced non-small-cell lung cancers treated with nivolumab.
    PLoS One. 2018;13:e0195945.
    PubMed     Abstract available


  344. NISHIO M, Nishizawa M, Sugiyama O, Kojima R, et al
    Computer-aided diagnosis of lung nodule using gradient tree boosting and Bayesian optimization.
    PLoS One. 2018;13:e0195875.
    PubMed     Abstract available


  345. KU BM, Choi MK, Sun JM, Lee SH, et al
    Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model.
    PLoS One. 2018;13:e0194730.
    PubMed     Abstract available


  346. JANSEN RJ, Alexander BH, Hayes RB, Miller AB, et al
    A mathematical model of case-ascertainment bias: Applied to case-control studies nested within a randomized screening trial.
    PLoS One. 2018;13:e0194608.
    PubMed     Abstract available


  347. NISHIO M, Sugiyama O, Yakami M, Ueno S, et al
    Computer-aided diagnosis of lung nodule classification between benign nodule, primary lung cancer, and metastatic lung cancer at different image size using deep convolutional neural network with transfer learning.
    PLoS One. 2018;13:e0200721.
    PubMed     Abstract available


  348. HIMES BE, Obraztsova K, Lian L, Shumyatcher M, et al
    Rapamycin-independent IGF2 expression in Tsc2-null mouse embryo fibroblasts and human lymphangioleiomyomatosis cells.
    PLoS One. 2018;13:e0197105.
    PubMed     Abstract available


  349. PEIKERT T, Duan F, Rajagopalan S, Karwoski RA, et al
    Novel high-resolution computed tomography-based radiomic classifier for screen-identified pulmonary nodules in the National Lung Screening Trial.
    PLoS One. 2018;13:e0196910.
    PubMed     Abstract available


  350. TARIQ H, Eldridge E, Welch I
    An efficient approach for feature construction of high-dimensional microarray data by random projections.
    PLoS One. 2018;13:e0196385.
    PubMed     Abstract available


  351. FRICKE IB, De Souza R, Costa Ayub L, Francia G, et al
    Spatiotemporal assessment of spontaneous metastasis formation using multimodal in vivo imaging in HER2+ and triple negative metastatic breast cancer xenograft models in mice.
    PLoS One. 2018;13:e0196892.
    PubMed     Abstract available


  352. JAFARINEZHAD A, YektaKooshali MH
    Lung cancer in idiopathic pulmonary fibrosis: A systematic review and meta-analysis.
    PLoS One. 2018;13:e0202360.
    PubMed     Abstract available


  353. CHEN X, Yang Y, Katz SI
    Dexamethasone pretreatment impairs the thymidylate synthase inhibition mediated flare in thymidine salvage pathway activity in non-small cell lung cancer.
    PLoS One. 2018;13:e0202384.
    PubMed     Abstract available


  354. YANO Y, Kurebe H, Edahiro R, Hosono Y, et al
    Post-progression survival after cessation of treatment with nivolumab for advanced non-small cell lung cancer: A retrospective study.
    PLoS One. 2018;13:e0203070.
    PubMed     Abstract available


  355. LEE DH, Tsao MS, Kambartel KO, Isobe H, et al
    Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PIvOTAL observational study.
    PLoS One. 2018;13:e0202865.
    PubMed     Abstract available


  356. SCHAD F, Thronicke A, Steele ML, Merkle A, et al
    Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis.
    PLoS One. 2018;13:e0203058.
    PubMed     Abstract available


  357. CONSONNI D, Carugno M, De Matteis S, Nordio F, et al
    Outdoor particulate matter (PM10) exposure and lung cancer risk in the EAGLE study.
    PLoS One. 2018;13:e0203539.
    PubMed     Abstract available


  358. ZABLOCKA-SLOWINSKA K, Placzkowska S, Prescha A, Pawelczyk K, et al
    Systemic redox status in lung cancer patients is related to altered glucose metabolism.
    PLoS One. 2018;13:e0204173.
    PubMed     Abstract available


  359. HUANG FF, Yang Q, Zhang J, Han XY, et al
    The structural equation model on self-efficacy during post-op rehabilitation among non-small cell lung cancer patients.
    PLoS One. 2018;13:e0204213.
    PubMed     Abstract available


  360. AN BC, Choi YD, Oh IJ, Kim JH, et al
    GPx3-mediated redox signaling arrests the cell cycle and acts as a tumor suppressor in lung cancer cell lines.
    PLoS One. 2018;13:e0204170.
    PubMed     Abstract available


  361. LIN PY, Chang YJ, Chen YC, Lin CH, et al
    Anti-cancer effects of 3,5-dimethylaminophenol in A549 lung cancer cells.
    PLoS One. 2018;13:e0205249.
    PubMed     Abstract available


  362. SCHERNBERG A, Mezquita L, Boros A, Botticella A, et al
    Neutrophilia as prognostic biomarker in locally advanced stage III lung cancer.
    PLoS One. 2018;13:e0204490.
    PubMed     Abstract available


  363. OWENS CA, Peterson CB, Tang C, Koay EJ, et al
    Lung tumor segmentation methods: Impact on the uncertainty of radiomics features for non-small cell lung cancer.
    PLoS One. 2018;13:e0205003.
    PubMed     Abstract available


  364. YAMAMOTO T, Kadoya N, Morishita Y, Sato Y, et al
    Assessment and agreement of the CT appearance pattern and its severity grading of radiation-induced lung injury after stereotactic body radiotherapy for lung cancer.
    PLoS One. 2018;13:e0204734.
    PubMed     Abstract available


  365. WANG J, Duan Y, Meng QH, Gong R, et al
    Integrated analysis of DNA methylation profiling and gene expression profiling identifies novel markers in lung cancer in Xuanwei, China.
    PLoS One. 2018;13:e0203155.
    PubMed     Abstract available


  366. DUPONT G, Flory L, Morel J, Lukaszewicz AC, et al
    Postoperative lymphopenia: An independent risk factor for postoperative pneumonia after lung cancer surgery, results of a case-control study.
    PLoS One. 2018;13:e0205237.
    PubMed     Abstract available


  367. LASITHIOTAKI I, Tsitoura E, Samara KD, Trachalaki A, et al
    NLRP3/Caspase-1 inflammasome activation is decreased in alveolar macrophages in patients with lung cancer.
    PLoS One. 2018;13:e0205242.
    PubMed     Abstract available


  368. KHUNGER M, Patil PD, Khunger A, Li M, et al
    Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients.
    PLoS One. 2018;13:e0197743.
    PubMed     Abstract available


  369. HART GR, Roffman DA, Decker R, Deng J, et al
    A multi-parameterized artificial neural network for lung cancer risk prediction.
    PLoS One. 2018;13:e0205264.
    PubMed     Abstract available


  370. LU S, Yu Y, Fu S, Ren H, et al
    Cost-effectiveness of ALK testing and first-line crizotinib therapy for non-small-cell lung cancer in China.
    PLoS One. 2018;13:e0205827.
    PubMed     Abstract available


  371. FU JY, Wan YL, Huang TY, Wu CF, et al
    Correlation between image characteristics and pathologic findings in non small cell lung cancer patients after anatomic resection.
    PLoS One. 2018;13:e0206386.
    PubMed     Abstract available


  372. GEZELIUS E, Flou Kristensen A, Bendahl PO, Hisada Y, et al
    Coagulation biomarkers and prediction of venous thromboembolism and survival in small cell lung cancer: A sub-study of RASTEN - A randomized trial with low molecular weight heparin.
    PLoS One. 2018;13:e0207387.
    PubMed     Abstract available


  373. JONES RA, Franks SE, Moorehead RA
    Comparative mRNA and miRNA transcriptome analysis of a mouse model of IGFIR-driven lung cancer.
    PLoS One. 2018;13:e0206948.
    PubMed     Abstract available


  374. ASHTON JR, Gottlin EB, Patz EF Jr, West JL, et al
    A comparative analysis of EGFR-targeting antibodies for gold nanoparticle CT imaging of lung cancer.
    PLoS One. 2018;13:e0206950.
    PubMed     Abstract available


  375. VELCHETI V, Patwardhan PD, Liu FX, Chen X, et al
    Real-world PD-L1 testing and distribution of PD-L1 tumor expression by immunohistochemistry assay type among patients with metastatic non-small cell lung cancer in the United States.
    PLoS One. 2018;13:e0206370.
    PubMed     Abstract available


  376. RAMELLA S, Fiore M, Greco C, Cordelli E, et al
    A radiomic approach for adaptive radiotherapy in non-small cell lung cancer patients.
    PLoS One. 2018;13:e0207455.
    PubMed     Abstract available


  377. OKOLI GN, Kostopoulou O, Delaney BC
    Is symptom-based diagnosis of lung cancer possible? A systematic review and meta-analysis of symptomatic lung cancer prior to diagnosis for comparison with real-time data from routine general practice.
    PLoS One. 2018;13:e0207686.
    PubMed     Abstract available


  378. PEREZ-MORALES J, Mejias-Morales D, Rivera-Rivera S, Gonzalez-Flores J, et al
    Hyper-phosphorylation of Rb S249 together with CDK5R2/p39 overexpression are associated with impaired cell adhesion and epithelial-to-mesenchymal transition: Implications as a potential lung cancer grading and staging biomarker.
    PLoS One. 2018;13:e0207483.
    PubMed     Abstract available


  379. GHOSH A, Sarkar S, Banerjee S, Behbod F, et al
    MIND model for triple-negative breast cancer in syngeneic mice for quick and sequential progression analysis of lung metastasis.
    PLoS One. 2018;13:e0198143.
    PubMed     Abstract available


  380. LIM JH, Ryu JS, Kim JH, Kim HJ, et al
    Gender as an independent prognostic factor in small-cell lung cancer: Inha Lung Cancer Cohort study using propensity score matching.
    PLoS One. 2018;13:e0208492.
    PubMed     Abstract available


  381. NAKAJIMA EC, Frankland MP, Johnson TF, Antic SL, et al
    Assessing the inter-observer variability of Computer-Aided Nodule Assessment and Risk Yield (CANARY) to characterize lung adenocarcinomas.
    PLoS One. 2018;13:e0198118.
    PubMed     Abstract available


  382. ILYINSKII PO, Kovalev GI, O'Neil CP, Roy CJ, et al
    Synthetic vaccine particles for durable cytolytic T lymphocyte responses and anti-tumor immunotherapy.
    PLoS One. 2018;13:e0197694.
    PubMed     Abstract available


  383. THOMENIUS MJ, Totman J, Harvey D, Mitchell LH, et al
    Small molecule inhibitors and CRISPR/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell proliferation.
    PLoS One. 2018;13:e0197372.
    PubMed     Abstract available


  384. PUJOL JL, Roch B, Roth C, Merel JP, et al
    Qualitative study of patients' decision-making when accepting second-line treatment after failure of first-line chemotherapy.
    PLoS One. 2018;13:e0197605.
    PubMed     Abstract available


  385. CHEN, Luo L, Liang C
    Aberrant S100A16 expression might be an independent prognostic indicator of unfavorable survival in non-small cell lung adenocarcinoma.
    PLoS One. 2018;13:e0197402.
    PubMed     Abstract available


  386. HU ZG, Li WX, Ruan YS, Zeng FJ, et al
    Incidence trends and risk prediction nomogram of metachronous second primary lung cancer in lung cancer survivors.
    PLoS One. 2018;13:e0209002.
    PubMed     Abstract available



  387. Correction: Is symptom-based diagnosis of lung cancer possible? A systematic review and meta-analysis of symptomatic lung cancer prior to diagnosis for comparison with real-time data from routine general practice.
    PLoS One. 2018;13:e0210108.
    PubMed     Abstract available


  388. LIU T, Chen Z, Dang J, Li G, et al
    The role of surgery in stage I to III small cell lung cancer: A systematic review and meta-analysis.
    PLoS One. 2018;13:e0210001.
    PubMed     Abstract available


  389. YANG B, Jhun BW, Shin SH, Jeong BH, et al
    Comparison of four models predicting the malignancy of pulmonary nodules: A single-center study of Korean adults.
    PLoS One. 2018;13:e0201242.
    PubMed     Abstract available


  390. PETRELLI F, Lazzari C, Ardito R, Borgonovo K, et al
    Efficacy of ALK inhibitors on NSCLC brain metastases: A systematic review and pooled analysis of 21 studies.
    PLoS One. 2018;13:e0201425.
    PubMed     Abstract available


  391. WONG ML, Shi Y, Fung KZ, Ngo S, et al
    Age, comorbidity, life expectancy, and pulmonary nodule follow-up in older veterans.
    PLoS One. 2018;13:e0200496.
    PubMed     Abstract available


  392. BALERMPAS P, Stera S, Muller von der Grun J, Loutfi-Krauss B, et al
    Repeated in-field radiosurgery for locally recurrent brain metastases: Feasibility, results and survival in a heavily treated patient cohort.
    PLoS One. 2018;13:e0198692.
    PubMed     Abstract available


  393. MESALLES-NARANJO O, Grant I, Wyper GMA, Stockton D, et al
    Trends and inequalities in the burden of mortality in Scotland 2000-2015.
    PLoS One. 2018;13:e0196906.
    PubMed     Abstract available


  394. BOSSCHIETER J, Bach S, Bijnsdorp IV, Segerink LI, et al
    A protocol for urine collection and storage prior to DNA methylation analysis.
    PLoS One. 2018;13:e0200906.
    PubMed     Abstract available


  395. CHEN J
    The prognostic analysis of different metastatic patterns in advanced liver cancer patients: A population based analysis.
    PLoS One. 2018;13:e0200909.
    PubMed     Abstract available


  396. RATH EM, Cheng YY, Pinese M, Sarun KH, et al
    BAMLET kills chemotherapy-resistant mesothelioma cells, holding oleic acid in an activated cytotoxic state.
    PLoS One. 2018;13:e0203003.
    PubMed     Abstract available


  397. FUKUOKA M, Yoshioka K, Hohjoh H
    NF-kappaB activation is an early event of changes in gene regulation for acquiring drug resistance in human adenocarcinoma PC-9 cells.
    PLoS One. 2018;13:e0201796.
    PubMed     Abstract available


  398. HSU JC, Lin JY, Hsu MY, Lin PC, et al
    Effectiveness and safety of immune checkpoint inhibitors: A retrospective study in Taiwan.
    PLoS One. 2018;13:e0202725.
    PubMed     Abstract available


  399. WATANABE K, Yasumoto A, Amano Y, Kage H, et al
    Mean platelet volume and lymphocyte-to-monocyte ratio are associated with shorter progression-free survival in EGFR-mutant lung adenocarcinoma treated by EGFR tyrosine kinase inhibitor.
    PLoS One. 2018;13:e0203625.
    PubMed     Abstract available


  400. OTSUKA M, Monzen H, Matsumoto K, Tamura M, et al
    Evaluation of lung toxicity risk with computed tomography ventilation image for thoracic cancer patients.
    PLoS One. 2018;13:e0204721.
    PubMed     Abstract available


  401. LEE JH, Kim TH, Lee S, Han K, et al
    High versus low attenuation thresholds to determine the solid component of ground-glass opacity nodules.
    PLoS One. 2018;13:e0205490.
    PubMed     Abstract available


  402. ZABECK H, Dienemann H, Hoffmann H, Pfannschmidt J, et al
    Molecular signatures in IASLC/ATS/ERS classified growth patterns of lung adenocarcinoma.
    PLoS One. 2018;13:e0206132.
    PubMed     Abstract available


  403. NAKANO H, Kawahara D, Ono K, Akagi Y, et al
    Effect of dose-delivery time for flattened and flattening filter-free photon beams based on microdosimetric kinetic model.
    PLoS One. 2018;13:e0206673.
    PubMed     Abstract available


  404. DOU TH, Coroller TP, van Griethuysen JJM, Mak RH, et al
    Peritumoral radiomics features predict distant metastasis in locally advanced NSCLC.
    PLoS One. 2018;13:e0206108.
    PubMed     Abstract available


  405. DOMPE N, Klijn C, Watson SA, Leng K, et al
    A CRISPR screen identifies MAPK7 as a target for combination with MEK inhibition in KRAS mutant NSCLC.
    PLoS One. 2018;13:e0199264.
    PubMed     Abstract available


  406. HUANG MH, Blackwood J, Godoshian M, Pfalzer L, et al
    Factors associated with self-reported falls, balance or walking difficulty in older survivors of breast, colorectal, lung, or prostate cancer: Results from Surveillance, Epidemiology, and End Results-Medicare Health Outcomes Survey linkage.
    PLoS One. 2018;13:e0208573.
    PubMed     Abstract available


    January 2017
  407. RYUGE S, Sato Y, Nagashio R, Hiyoshi Y, et al
    Prognostic significance of nestin expression in patients with resected non-small cell lung cancer treated with platinum-based adjuvant chemotherapy; relationship between nestin expression and epithelial to mesenchymal transition related markers.
    PLoS One. 2017;12:e0173886.
    PubMed     Abstract available


  408. HOU GX, Liu P, Yang J, Wen S, et al
    Mining expression and prognosis of topoisomerase isoforms in non-small-cell lung cancer by using Oncomine and Kaplan-Meier plotter.
    PLoS One. 2017;12:e0174515.
    PubMed     Abstract available


  409. OGUMA T, Nagaoka T, Kurahashi M, Kobayashi N, et al
    Clinical contributions of exhaled volatile organic compounds in the diagnosis of lung cancer.
    PLoS One. 2017;12:e0174802.
    PubMed     Abstract available


  410. FAN L, Chen L, Ni X, Guo S, et al
    Genetic variant of miR-4293 rs12220909 is associated with susceptibility to non-small cell lung cancer in a Chinese Han population.
    PLoS One. 2017;12:e0175666.
    PubMed     Abstract available


  411. DAVIES J, Patel M, Gridelli C, de Marinis F, et al
    Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: A systematic review of recently published studies.
    PLoS One. 2017;12:e0175679.
    PubMed     Abstract available


  412. SHEN G, Lan Y, Zhang K, Ren P, et al
    Correction: Comparison of 18F-FDG PET/CT and DWI for detection of mediastinal nodal metastasis in non-small cell lung cancer: A meta-analysis.
    PLoS One. 2017;12:e0176150.
    PubMed     Abstract available


  413. HE M, Yang Z, Zhang L, Song C, et al
    Additive effects of cherlerythrine chloride combination with erlotinib in human non-small cell lung cancer cells.
    PLoS One. 2017;12:e0175466.
    PubMed     Abstract available


  414. SHIRAI K, Kawashima M, Saitoh JI, Abe T, et al
    Clinical outcomes using carbon-ion radiotherapy and dose-volume histogram comparison between carbon-ion radiotherapy and photon therapy for T2b-4N0M0 non-small cell lung cancer-A pilot study.
    PLoS One. 2017;12:e0175589.
    PubMed     Abstract available


  415. CAO G, Cheng D, Ye L, Pan Y, et al
    Surgical resection of pulmonary metastases from colorectal cancer: 11 years of experiences.
    PLoS One. 2017;12:e0175284.
    PubMed     Abstract available


  416. XU Z, Yan Y, Xiao L, Dai S, et al
    Radiosensitizing effect of diosmetin on radioresistant lung cancer cells via Akt signaling pathway.
    PLoS One. 2017;12:e0175977.
    PubMed     Abstract available


  417. INOUE Y, Shiihara J, Miyazawa H, Ohta H, et al
    A highly specific and sensitive massive parallel sequencer-based test for somatic mutations in non-small cell lung cancer.
    PLoS One. 2017;12:e0176525.
    PubMed     Abstract available


  418. FUKUDA T, Nomura M, Kato Y, Tojo H, et al
    A selected reaction monitoring mass spectrometric assessment of biomarker candidates diagnosing large-cell neuroendocrine lung carcinoma by the scaling method using endogenous references.
    PLoS One. 2017;12:e0176219.
    PubMed     Abstract available


  419. BAILEY G, Healy A, Young BD, Sharma E, et al
    Relative predictive value of lung cancer screening CT versus myocardial perfusion attenuation correction CT in the evaluation of coronary calcium.
    PLoS One. 2017;12:e0175678.
    PubMed     Abstract available


  420. TAKAMOCHI K, Mogushi K, Kawaji H, Imashimizu K, et al
    Correlation of EGFR or KRAS mutation status with 18F-FDG uptake on PET-CT scan in lung adenocarcinoma.
    PLoS One. 2017;12:e0175622.
    PubMed     Abstract available


  421. DENEKA AY, Haber L, Kopp MC, Gaponova AV, et al
    Tumor-targeted SN38 inhibits growth of early stage non-small cell lung cancer (NSCLC) in a KRas/p53 transgenic mouse model.
    PLoS One. 2017;12:e0176747.
    PubMed     Abstract available


  422. DURDA K, Kaklewski K, Gupta S, Szydlowski M, et al
    Serum folate concentration and the incidence of lung cancer.
    PLoS One. 2017;12:e0177441.
    PubMed     Abstract available


  423. KIM JS, Cho MS, Nam JH, Kim HJ, et al
    Prognostic impact of EGFR mutation in non-small-cell lung cancer patients with family history of lung cancer.
    PLoS One. 2017;12:e0177015.
    PubMed     Abstract available


  424. JUN HY, Kim TH, Choi JW, Lee YH, et al
    Evaluation of connectivity map-discovered celastrol as a radiosensitizing agent in a murine lung carcinoma model: Feasibility study of diffusion-weighted magnetic resonance imaging.
    PLoS One. 2017;12:e0178204.
    PubMed     Abstract available


  425. HOLMBOE S, Hansen PL, Thisgaard H, Block I, et al
    Evaluation of somatostatin and nucleolin receptors for therapeutic delivery in non-small cell lung cancer stem cells applying the somatostatin-analog DOTATATE and the nucleolin-targeting aptamer AS1411.
    PLoS One. 2017;12:e0178286.
    PubMed     Abstract available


  426. PARK SL, Murphy SE, Wilkens LR, Stram DO, et al
    Association of CYP2A6 activity with lung cancer incidence in smokers: The multiethnic cohort study.
    PLoS One. 2017;12:e0178435.
    PubMed     Abstract available


  427. CAMERON SJS, Lewis KE, Huws SA, Hegarty MJ, et al
    A pilot study using metagenomic sequencing of the sputum microbiome suggests potential bacterial biomarkers for lung cancer.
    PLoS One. 2017;12:e0177062.
    PubMed     Abstract available


  428. CHANG HW, Lin ZM, Wu MJ, Wang LY, et al
    Characterization of a transgenic mouse model exhibiting spontaneous lung adenocarcinomas with a metastatic phenotype.
    PLoS One. 2017;12:e0175586.
    PubMed     Abstract available


  429. CARRERAS-TORRES R, Johansson M, Haycock PC, Wade KH, et al
    Obesity, metabolic factors and risk of different histological types of lung cancer: A Mendelian randomization study.
    PLoS One. 2017;12:e0177875.
    PubMed     Abstract available


  430. CHANG YP, Chen YM, Lai CH, Lin CY, et al
    The impact of de novo liver metastasis on clinical outcome in patients with advanced non-small-cell lung cancer.
    PLoS One. 2017;12:e0178676.
    PubMed     Abstract available


  431. WEISS GJ, Byron SA, Aldrich J, Sangal A, et al
    A prospective pilot study of genome-wide exome and transcriptome profiling in patients with small cell lung cancer progressing after first-line therapy.
    PLoS One. 2017;12:e0179170.
    PubMed     Abstract available


  432. ABERNETHY AP, Arunachalam A, Burke T, McKay C, et al
    Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting.
    PLoS One. 2017;12:e0178420.
    PubMed     Abstract available


  433. WU YT, Li X, Liu ZL, Xu Z, et al
    Hepatitis B virus reactivation and antiviral prophylaxis during lung cancer chemotherapy: A systematic review and meta-analysis.
    PLoS One. 2017;12:e0179680.
    PubMed     Abstract available


  434. YAGI S, Koh Y, Akamatsu H, Kanai K, et al
    Development of an automated size-based filtration system for isolation of circulating tumor cells in lung cancer patients.
    PLoS One. 2017;12:e0179744.
    PubMed     Abstract available


  435. BEN-LULU S, Ziv T, Weisman-Shomer P, Benhar M, et al
    Correction: Nitrosothiol-Trapping-Based Proteomic Analysis of S-Nitrosylation in Human Lung Carcinoma Cells.
    PLoS One. 2017;12:e0179803.
    PubMed     Abstract available


  436. SCHMIDT LH, Brand C, Stucke-Ring J, Schliemann C, et al
    Potential therapeutic impact of CD13 expression in non-small cell lung cancer.
    PLoS One. 2017;12:e0177146.
    PubMed     Abstract available


  437. LOISELLE JJ, Roy JG, Sutherland LC
    RBM10 promotes transformation-associated processes in small cell lung cancer and is directly regulated by RBM5.
    PLoS One. 2017;12:e0180258.
    PubMed     Abstract available


  438. DE MARCO C, Laudanna C, Rinaldo N, Oliveira DM, et al
    Specific gene expression signatures induced by the multiple oncogenic alterations that occur within the PTEN/PI3K/AKT pathway in lung cancer.
    PLoS One. 2017;12:e0178865.
    PubMed     Abstract available


  439. LEE AF, Chen MC, Chen CJ, Yang CJ, et al
    Reverse epithelial-mesenchymal transition contributes to the regain of drug sensitivity in tyrosine kinase inhibitor-resistant non-small cell lung cancer cells.
    PLoS One. 2017;12:e0180383.
    PubMed     Abstract available


  440. GUISIER F, Bohn P, Patout M, Piton N, et al
    In- and ex-vivo molecular imaging of apoptosis to assess sensitivity of non-small cell lung cancer to EGFR inhibitors using probe-based confocal laser endomicroscopy.
    PLoS One. 2017;12:e0180576.
    PubMed     Abstract available


  441. POWELL AC, Mirhadi AJ, Loy BA, Happe LE, et al
    Presentation at computed tomography (CT) scan of the thorax and first year diagnostic and treatment utilization among patients diagnosed with lung cancer.
    PLoS One. 2017;12:e0181319.
    PubMed     Abstract available


  442. GOTO A, Tanaka M, Yoshida M, Umakoshi M, et al
    The low expression of miR-451 predicts a worse prognosis in non-small cell lung cancer cases.
    PLoS One. 2017;12:e0181270.
    PubMed     Abstract available


  443. SAUSVILLE LN, Jones CC, Aldrich MC, Blot WJ, et al
    Genetic variation in the eicosanoid pathway is associated with non-small-cell lung cancer (NSCLC) survival.
    PLoS One. 2017;12:e0180471.
    PubMed     Abstract available


  444. LIU PL, Liu WL, Chang JM, Chen YH, et al
    MicroRNA-200c inhibits epithelial-mesenchymal transition, invasion, and migration of lung cancer by targeting HMGB1.
    PLoS One. 2017;12:e0180844.
    PubMed     Abstract available


  445. MESSARITAKIS I, Politaki E, Kotsakis A, Dermitzaki EK, et al
    Phenotypic characterization of circulating tumor cells in the peripheral blood of patients with small cell lung cancer.
    PLoS One. 2017;12:e0181211.
    PubMed     Abstract available


  446. SILVA EM, Mariano VS, Pastrez PRA, Pinto MC, et al
    High systemic IL-6 is associated with worse prognosis in patients with non-small cell lung cancer.
    PLoS One. 2017;12:e0181125.
    PubMed     Abstract available


  447. TANG ZM, Ling ZG, Wang CM, Wu YB, et al
    Serum tumor-associated autoantibodies as diagnostic biomarkers for lung cancer: A systematic review and meta-analysis.
    PLoS One. 2017;12:e0182117.
    PubMed     Abstract available


  448. BANJARA M, Ghosh C, Dadas A, Mazzone P, et al
    Detection of brain-directed autoantibodies in the serum of non-small cell lung cancer patients.
    PLoS One. 2017;12:e0181409.
    PubMed     Abstract available


  449. SARIN N, Engel F, Kalayda GV, Mannewitz M, et al
    Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G2/M cell cycle arrest.
    PLoS One. 2017;12:e0181081.
    PubMed     Abstract available


  450. PATNAIK SK, Kannisto ED, Mallick R, Vachani A, et al
    Whole blood microRNA expression may not be useful for screening non-small cell lung cancer.
    PLoS One. 2017;12:e0181926.
    PubMed     Abstract available


  451. AL-SAAD S, Richardsen E, Kilvaer TK, Donnem T, et al
    The impact of MET, IGF-1, IGF1R expression and EGFR mutations on survival of patients with non-small-cell lung cancer.
    PLoS One. 2017;12:e0181527.
    PubMed     Abstract available


  452. OH TK, Jeon JH, Lee JM, Kim MS, et al
    Investigation of opioid use and long-term oncologic outcomes for non-small cell lung cancer patients treated with surgery.
    PLoS One. 2017;12:e0181672.
    PubMed     Abstract available


  453. KOLEK V, Grygarkova I, Koubkova L, Skrickova J, et al
    Carboplatin with intravenous and subsequent oral administration of vinorelbine in resected non-small-cell-lung cancer in real-world set-up.
    PLoS One. 2017;12:e0181803.
    PubMed     Abstract available


  454. GONG X, Liu J, Zhang D, Yang D, et al
    GLIPR1 modulates the response of cisplatin-resistant human lung cancer cells to cisplatin.
    PLoS One. 2017;12:e0182410.
    PubMed     Abstract available


  455. LIU L, He Y, Ge G, Li L, et al
    Lactate dehydrogenase and creatine kinase as poor prognostic factors in lung cancer: A retrospective observational study.
    PLoS One. 2017;12:e0182168.
    PubMed     Abstract available


  456. PELAEZ R, Morales X, Salvo E, Garasa S, et al
    beta3 integrin expression is required for invadopodia-mediated ECM degradation in lung carcinoma cells.
    PLoS One. 2017;12:e0181579.
    PubMed     Abstract available


  457. MIRET M, Horvath-Puho E, Deruaz-Luyet A, Sorensen HT, et al
    Potential paraneoplastic syndromes and selected autoimmune conditions in patients with non-small cell lung cancer and small cell lung cancer: A population-based cohort study.
    PLoS One. 2017;12:e0181564.
    PubMed     Abstract available


  458. TONG M, Wang J, Jiang N, Pan H, et al
    Correlation between p-STAT3 overexpression and prognosis in lung cancer: A systematic review and meta-analysis.
    PLoS One. 2017;12:e0182282.
    PubMed     Abstract available


  459. SCHMIDT LH, Brand C, Stucke-Ring J, Schliemann C, et al
    Correction: Potential therapeutic impact of CD13 expression in non-small cell lung cancer.
    PLoS One. 2017;12:e0183201.
    PubMed     Abstract available


  460. CHEN B, Yang L, Zhang R, Gan Y, et al
    Hyperphosphorylation of RPS6KB1, rather than overexpression, predicts worse prognosis in non-small cell lung cancer patients.
    PLoS One. 2017;12:e0182891.
    PubMed     Abstract available


  461. CHENG CC, Chang J, Huang SC, Lin HC, et al
    YM155 as an inhibitor of cancer stemness simultaneously inhibits autophosphorylation of epidermal growth factor receptor and G9a-mediated stemness in lung cancer cells.
    PLoS One. 2017;12:e0182149.
    PubMed     Abstract available


  462. NAKANO T, Kanai Y, Amano Y, Yoshimoto T, et al
    Establishment of highly metastatic KRAS mutant lung cancer cell sublines in long-term three-dimensional low attachment cultures.
    PLoS One. 2017;12:e0181342.
    PubMed     Abstract available


  463. PILYUGIN M, Descloux P, Andre PA, Laszlo V, et al
    BARD1 serum autoantibodies for the detection of lung cancer.
    PLoS One. 2017;12:e0182356.
    PubMed     Abstract available


  464. KIM EK, Kim KA, Lee CY, Shim HS, et al
    The frequency and clinical impact of HER2 alterations in lung adenocarcinoma.
    PLoS One. 2017;12:e0171280.
    PubMed     Abstract available


  465. WANICHTHANARAK K, Fan S, Grapov D, Barupal DK, et al
    Metabox: A Toolbox for Metabolomic Data Analysis, Interpretation and Integrative Exploration.
    PLoS One. 2017;12:e0171046.
    PubMed     Abstract available


  466. ORTIZ-ZAPATER E, Lee RW, Owen W, Weitsman G, et al
    MET-EGFR dimerization in lung adenocarcinoma is dependent on EGFR mtations and altered by MET kinase inhibition.
    PLoS One. 2017;12:e0170798.
    PubMed     Abstract available


  467. HARATI S, Cooper LA, Moran JD, Giuste FO, et al
    MEDICI: Mining Essentiality Data to Identify Critical Interactions for Cancer Drug Target Discovery and Development.
    PLoS One. 2017;12:e0170339.
    PubMed     Abstract available


  468. FANG Y, Zhang C, Wu T, Wang Q, et al
    Transcriptome Sequencing Reveals Key Pathways and Genes Associated with Cisplatin Resistance in Lung Adenocarcinoma A549 Cells.
    PLoS One. 2017;12:e0170609.
    PubMed     Abstract available


  469. NIKOLOVSKA K, Spillmann D, Haier J, Ladanyi A, et al
    Melanoma Cell Adhesion and Migration Is Modulated by the Uronyl 2-O Sulfotransferase.
    PLoS One. 2017;12:e0170054.
    PubMed     Abstract available


  470. KISELEVA R, Greineder CF, Villa CH, Hood ED, et al
    Mechanism of Collaborative Enhancement of Binding of Paired Antibodies to Distinct Epitopes of Platelet Endothelial Cell Adhesion Molecule-1.
    PLoS One. 2017;12:e0169537.
    PubMed     Abstract available


  471. ALSUBAIE N, Trahearn N, Raza SE, Snead D, et al
    Stain Deconvolution Using Statistical Analysis of Multi-Resolution Stain Colour Representation.
    PLoS One. 2017;12:e0169875.
    PubMed     Abstract available


  472. CHOUAID C, Debieuvre D, Durand-Zaleski I, Fernandes J, et al
    Survival inequalities in patients with lung cancer in France: A nationwide cohort study (the TERRITOIRE Study).
    PLoS One. 2017;12:e0182798.
    PubMed     Abstract available


  473. SHIN J, Song SY, Ahn HS, An BC, et al
    Integrative analysis for the discovery of lung cancer serological markers and validation by MRM-MS.
    PLoS One. 2017;12:e0183896.
    PubMed     Abstract available


  474. JOVELET C, Madic J, Remon J, Honore A, et al
    Crystal digital droplet PCR for detection and quantification of circulating EGFR sensitizing and resistance mutations in advanced non-small cell lung cancer.
    PLoS One. 2017;12:e0183319.
    PubMed     Abstract available


  475. CHEN L, Lu J, Huang T, Cai YD, et al
    A computational method for the identification of candidate drugs for non-small cell lung cancer.
    PLoS One. 2017;12:e0183411.
    PubMed     Abstract available


  476. YANG JH, Li XY, Wang X, Hou WJ, et al
    Long-term persistent infection of HPV 16 E6 up-regulate SP1 and hTERT by inhibiting LKB1 in lung cancer cells.
    PLoS One. 2017;12:e0182775.
    PubMed     Abstract available


  477. KONG GM, Yu M, Gu Z, Chen Z, et al
    Selective small-chemical inhibitors of protein arginine methyltransferase 5 with anti-lung cancer activity.
    PLoS One. 2017;12:e0181601.
    PubMed     Abstract available


  478. ZHANG C, Wei B, Li P, Yang K, et al
    Prognostic value of plasma EGFR ctDNA in NSCLC patients treated with EGFR-TKIs.
    PLoS One. 2017;12:e0173524.
    PubMed     Abstract available


  479. WIEGERING A, Riegel J, Wagner J, Kunzmann V, et al
    The impact of pulmonary metastasectomy in patients with previously resected colorectal cancer liver metastases.
    PLoS One. 2017;12:e0173933.
    PubMed     Abstract available


  480. ASOR E, Stav MY, Simon E, Fahoum I, et al
    Risk for molecular contamination of tissue samples evaluated for targeted anti-cancer therapy.
    PLoS One. 2017;12:e0173760.
    PubMed     Abstract available


  481. ECHTLER K, Konrad I, Lorenz M, Schneider S, et al
    Platelet GPIIb supports initial pulmonary retention but inhibits subsequent proliferation of melanoma cells during hematogenic metastasis.
    PLoS One. 2017;12:e0172788.
    PubMed     Abstract available


  482. PUNIA R, Raina K, Agarwal R, Singh RP, et al
    Acacetin enhances the therapeutic efficacy of doxorubicin in non-small-cell lung carcinoma cells.
    PLoS One. 2017;12:e0182870.
    PubMed     Abstract available


  483. VAN DER WEKKEN AJ, Kuiper JL, Saber A, Terpstra MM, et al
    Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression.
    PLoS One. 2017;12:e0182885.
    PubMed     Abstract available


  484. HSU MK, Lin HY, Chen FC
    NMD Classifier: A reliable and systematic classification tool for nonsense-mediated decay events.
    PLoS One. 2017;12:e0174798.
    PubMed     Abstract available


  485. PARK JE, Chun SE, Reichel D, Min JS, et al
    Polymer micelle formulation for the proteasome inhibitor drug carfilzomib: Anticancer efficacy and pharmacokinetic studies in mice.
    PLoS One. 2017;12:e0173247.
    PubMed     Abstract available


  486. JIN J, Hu K, Zhou Y, Li W, et al
    Clinical utility of the modified Glasgow prognostic score in lung cancer: A meta-analysis.
    PLoS One. 2017;12:e0184412.
    PubMed     Abstract available


  487. CAO X, MacNaughton P, Laurent JC, Allen JG, et al
    Radon-induced lung cancer deaths may be overestimated due to failure to account for confounding by exposure to diesel engine exhaust in BEIR VI miner studies.
    PLoS One. 2017;12:e0184298.
    PubMed     Abstract available


  488. DE BIASE D, Genestreti G, Visani M, Acquaviva G, et al
    The percentage of Epidermal Growth Factor Receptor (EGFR)-mutated neoplastic cells correlates to response to tyrosine kinase inhibitors in lung adenocarcinoma.
    PLoS One. 2017;12:e0177822.
    PubMed     Abstract available


  489. HSIEH CC, Sun YH, Lin SW, Yeh YC, et al
    Surgical outcomes of pulmonary mucoepidermoid carcinoma: A review of 41 cases.
    PLoS One. 2017;12:e0176918.
    PubMed     Abstract available


  490. LEE DH, Hwang SH, Lim MK, Oh JK, et al
    Performance of urine cotinine and hypomethylation of AHRR and F2RL3 as biomarkers for smoking exposure in a population-based cohort.
    PLoS One. 2017;12:e0176783.
    PubMed     Abstract available


  491. CAI G, Xiao F, Cheng C, Li Y, et al
    Population effect model identifies gene expression predictors of survival outcomes in lung adenocarcinoma for both Caucasian and Asian patients.
    PLoS One. 2017;12:e0175850.
    PubMed     Abstract available


  492. AGRAWAL V, Coroller TP, Hou Y, Lee SW, et al
    Lymph node volume predicts survival but not nodal clearance in Stage IIIA-IIIB NSCLC.
    PLoS One. 2017;12:e0174268.
    PubMed     Abstract available


  493. LYNCH CM, van Berkel VH, Frieboes HB
    Application of unsupervised analysis techniques to lung cancer patient data.
    PLoS One. 2017;12:e0184370.
    PubMed     Abstract available


  494. CAI NL, Lau ATY, Yu FY, Wu DD, et al
    Purification and characterization of a highly specific polyclonal antibody against human extracellular signal-regulated kinase 8 and its detection in lung cancer.
    PLoS One. 2017;12:e0184755.
    PubMed     Abstract available


  495. SHEN Z, Wang H, Xi W, Deng X, et al
    Multi-phase simultaneous segmentation of tumor in lung 4D-CT data with context information.
    PLoS One. 2017;12:e0178411.
    PubMed     Abstract available


  496. KOO HJ, Kim MY, Koo JH, Sung YS, et al
    Computerized margin and texture analyses for differentiating bacterial pneumonia and invasive mucinous adenocarcinoma presenting as consolidation.
    PLoS One. 2017;12:e0177379.
    PubMed     Abstract available


  497. ZHAO XK, Mao YM, Meng H, Song X, et al
    Shared susceptibility loci at 2q33 region for lung and esophageal cancers in high-incidence areas of esophageal cancer in northern China.
    PLoS One. 2017;12:e0177504.
    PubMed     Abstract available


  498. FARQUHAR M, Penfold C, Benson J, Lovick R, et al
    Six key topics informal carers of patients with breathlessness in advanced disease want to learn about and why: MRC phase I study to inform an educational intervention.
    PLoS One. 2017;12:e0177081.
    PubMed     Abstract available


  499. WANG XF, Zhu YT, Wang JJ, Zeng DX, et al
    The prognostic value of interleukin-17 in lung cancer: A systematic review with meta-analysis based on Chinese patients.
    PLoS One. 2017;12:e0185168.
    PubMed     Abstract available


  500. ELLSWORTH SG, Rabatic BM, Chen J, Zhao J, et al
    Principal component analysis identifies patterns of cytokine expression in non-small cell lung cancer patients undergoing definitive radiation therapy.
    PLoS One. 2017;12:e0183239.
    PubMed     Abstract available


  501. WANG C, Zhang X, Li H, Li X, et al
    Quantitative thyroglobulin response to radioactive iodine treatment in predicting radioactive iodine-refractory thyroid cancer with pulmonary metastasis.
    PLoS One. 2017;12:e0179664.
    PubMed     Abstract available


  502. WANG L, Tang C, Xu B, Yang L, et al
    Mass spectrometry-based serum peptidome profiling accurately and reliably predicts outcomes of pemetrexed plus platinum chemotherapy in patients with advanced lung adenocarcinoma.
    PLoS One. 2017;12:e0179000.
    PubMed     Abstract available


  503. YIP SSF, Parmar C, Blezek D, Estepar RSJ, et al
    Application of the 3D slicer chest imaging platform segmentation algorithm for large lung nodule delineation.
    PLoS One. 2017;12:e0178944.
    PubMed     Abstract available


  504. KEARNEY P, Hunsucker SW, Li XJ, Porter A, et al
    An integrated risk predictor for pulmonary nodules.
    PLoS One. 2017;12:e0177635.
    PubMed     Abstract available


  505. KEE JY, Han YH, Kim DS, Mun JG, et al
    beta-Lapachone suppresses the lung metastasis of melanoma via the MAPK signaling pathway.
    PLoS One. 2017;12:e0176937.
    PubMed     Abstract available


  506. WANG T, Moon JY, Wu Y, Amos CI, et al
    Pleiotropy of genetic variants on obesity and smoking phenotypes: Results from the Oncoarray Project of The International Lung Cancer Consortium.
    PLoS One. 2017;12:e0185660.
    PubMed     Abstract available


  507. SHAN S, She J, Xue ZQ, Su CX, et al
    Clinical characteristics and survival of lung cancer patients associated with multiple primary malignancies.
    PLoS One. 2017;12:e0185485.
    PubMed     Abstract available


  508. WANG F, Xu X, Yang J, Min L, et al
    Height and lung cancer risk: A meta-analysis of observational studies.
    PLoS One. 2017;12:e0185316.
    PubMed     Abstract available


  509. CIRCU M, Cardelli J, Barr M, O'Byrne K, et al
    Modulating lysosomal function through lysosome membrane permeabilization or autophagy suppression restores sensitivity to cisplatin in refractory non-small-cell lung cancer cells.
    PLoS One. 2017;12:e0184922.
    PubMed     Abstract available


  510. NOWICKI-OSUCH K, Li Y, Challinor M, Gerrard DT, et al
    EINCR1 is an EGF inducible lincRNA overexpressed in lung adenocarcinomas.
    PLoS One. 2017;12:e0181902.
    PubMed     Abstract available


  511. PIRIE-SHEPHERD SR, Painter C, Whalen P, Vizcarra P, et al
    Detecting expression of 5T4 in CTCs and tumor samples from NSCLC patients.
    PLoS One. 2017;12:e0179561.
    PubMed     Abstract available


  512. TAKADA K, Okamoto T, Tominaga M, Teraishi K, et al
    Clinical implications of the novel cytokine IL-38 expressed in lung adenocarcinoma: Possible association with PD-L1 expression.
    PLoS One. 2017;12:e0181598.
    PubMed     Abstract available


  513. CHOI BH, Young HS, Quan YH, Rho J, et al
    Real-time computed tomography fluoroscopy-guided solitary lung tumor model in a rabbit.
    PLoS One. 2017;12:e0179220.
    PubMed     Abstract available


  514. LENDECKEL D, Kromrey ML, Ittermann T, Schafer S, et al
    Pulmonary emphysema is a predictor of pneumothorax after CT-guided transthoracic pulmonary biopsies of pulmonary nodules.
    PLoS One. 2017;12:e0178078.
    PubMed     Abstract available


  515. MINCHOM A, Thavasu P, Ahmad Z, Stewart A, et al
    A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments.
    PLoS One. 2017;12:e0186106.
    PubMed     Abstract available


  516. ILIE M, Khambata-Ford S, Copie-Bergman C, Huang L, et al
    Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms.
    PLoS One. 2017;12:e0183023.
    PubMed     Abstract available


  517. MUSCELLA A, Vetrugno C, Cossa LG, Antonaci G, et al
    Apoptosis by [Pt(O,O'-acac)(gamma-acac)(DMS)] requires PKC-delta mediated p53 activation in malignant pleural mesothelioma.
    PLoS One. 2017;12:e0181114.
    PubMed     Abstract available


  518. YVOREL V, Patoir A, Casteillo F, Tissot C, et al
    PD-L1 expression in pleomorphic, spindle cell and giant cell carcinoma of the lung is related to TTF-1, p40 expression and might indicate a worse prognosis.
    PLoS One. 2017;12:e0180346.
    PubMed     Abstract available


  519. BORIN TF, Shankar A, Angara K, Rashid MH, et al
    HET0016 decreases lung metastasis from breast cancer in immune-competent mouse model.
    PLoS One. 2017;12:e0178830.
    PubMed     Abstract available


  520. KASPI E, Frankel D, Guinde J, Perrin S, et al
    Low lamin A expression in lung adenocarcinoma cells from pleural effusions is a pejorative factor associated with high number of metastatic sites and poor Performance status.
    PLoS One. 2017;12:e0183136.
    PubMed     Abstract available


  521. KROSNICK JA, Malhotra N, Mo CH, Bruera EF, et al
    Perceptions of health risks of cigarette smoking: A new measure reveals widespread misunderstanding.
    PLoS One. 2017;12:e0182063.
    PubMed     Abstract available


  522. TUDOR RA, D'Silva A, Tremblay A, MacEachern P, et al
    Beyond disease-progression: Clinical outcomes after EGFR-TKIs in a cohort of EGFR mutated NSCLC patients.
    PLoS One. 2017;12:e0181867.
    PubMed     Abstract available


  523. JIN C, Zhang G, Zhang Y, Hua P, et al
    Isoalantolactone induces intrinsic apoptosis through p53 signaling pathway in human lung squamous carcinoma cells.
    PLoS One. 2017;12:e0181731.
    PubMed     Abstract available


  524. YU PY, Gardner HL, Roberts R, Cam H, et al
    Target specificity, in vivo pharmacokinetics, and efficacy of the putative STAT3 inhibitor LY5 in osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma.
    PLoS One. 2017;12:e0181885.
    PubMed     Abstract available


  525. NAKAMURA S, Hayashi K, Imaoka Y, Kitamura Y, et al
    Intratumoral heterogeneity of programmed cell death ligand-1 expression is common in lung cancer.
    PLoS One. 2017;12:e0186192.
    PubMed     Abstract available


  526. PEARCE A, Haas M, Viney R, Pearson SA, et al
    Incidence and severity of self-reported chemotherapy side effects in routine care: A prospective cohort study.
    PLoS One. 2017;12:e0184360.
    PubMed     Abstract available


  527. D'HOOGHE JNS, Goorsenberg AWM, de Bruin DM, Roelofs JJTH, et al
    Optical coherence tomography for identification and quantification of human airway wall layers.
    PLoS One. 2017;12:e0184145.
    PubMed     Abstract available


  528. LIAO HF, Pan CH, Chou PY, Chen YF, et al
    Toxicological effects of NCKU-21, a phenanthrene derivative, on cell growth and migration of A549 and CL1-5 human lung adenocarcinoma cells.
    PLoS One. 2017;12:e0185021.
    PubMed     Abstract available


  529. LAMBERT A, Jarlier M, Gourgou Bourgade S, Conroy T, et al
    Response to FOLFIRINOX by gender in patients with metastatic pancreatic cancer: Results from the PRODIGE 4/ ACCORD 11 randomized trial.
    PLoS One. 2017;12:e0183288.
    PubMed     Abstract available


  530. SUTTON BC, Birse RT, Maggert K, Ray T, et al
    Assessment of common somatic mutations of EGFR, KRAS, BRAF, NRAS in pulmonary non-small cell carcinoma using iPLEX(R) HS, a new highly sensitive assay for the MassARRAY(R) System.
    PLoS One. 2017;12:e0183715.
    PubMed     Abstract available


  531. BUONOMO OC, Caredda E, Portarena I, Vanni G, et al
    New insights into the metastatic behavior after breast cancer surgery, according to well-established clinicopathological variables and molecular subtypes.
    PLoS One. 2017;12:e0184680.
    PubMed     Abstract available


  532. HUANG JY, Wang R, Gao YT, Yuan JM, et al
    ABO blood type and the risk of cancer - Findings from the Shanghai Cohort Study.
    PLoS One. 2017;12:e0184295.
    PubMed     Abstract available


  533. KWIECIEN JM, Bassey-Archibong BI, Dabrowski W, Rayner LG, et al
    Loss of Kaiso expression in breast cancer cells prevents intra-vascular invasion in the lung and secondary metastasis.
    PLoS One. 2017;12:e0183883.
    PubMed     Abstract available


  534. FORNARO L, Vivaldi C, Lin D, Xue H, et al
    Prognostic relevance of a T-type calcium channels gene signature in solid tumours: A correlation ready for clinical validation.
    PLoS One. 2017;12:e0182818.
    PubMed     Abstract available


  535. LI Y, Xu H, Su S, Ye J, et al
    Clinical validation of a highly sensitive assay to detect EGFR mutations in plasma cell-free DNA from patients with advanced lung adenocarcinoma.
    PLoS One. 2017;12:e0183331.
    PubMed     Abstract available


  536. KWAK KM, Paek D, Hwang SS, Ju YS, et al
    Estimated future incidence of malignant mesothelioma in South Korea: Projection from 2014 to 2033.
    PLoS One. 2017;12:e0183404.
    PubMed     Abstract available


  537. NOGUEIRA JORGE NA, Wajnberg G, Ferreira CG, de Sa Carvalho B, et al
    snoRNA and piRNA expression levels modified by tobacco use in women with lung adenocarcinoma.
    PLoS One. 2017;12:e0183410.
    PubMed     Abstract available


  538. VANDEREYKEN M, Jacques S, Van Overmeire E, Amand M, et al
    Dusp3 deletion in mice promotes experimental lung tumour metastasis in a macrophage dependent manner.
    PLoS One. 2017;12:e0185786.
    PubMed     Abstract available


  539. MOON MH, Beck KS, Moon YK, Park JK, et al
    Incidence and clinical features of the incidentally found vascular stump thrombus during routine follow up after oncologic lung surgery.
    PLoS One. 2017;12:e0185140.
    PubMed     Abstract available


  540. JIANG R, Dong X, Zhu W, Duan Q, et al
    Combining PET/CT with serum tumor markers to improve the evaluation of histological type of suspicious lung cancers.
    PLoS One. 2017;12:e0184338.
    PubMed     Abstract available


  541. KIND M, Klukowska-Rotzler J, Berezowska S, Arcaro A, et al
    Questioning the role of selected somatic PIK3C2B mutations in squamous non-small cell lung cancer oncogenesis.
    PLoS One. 2017;12:e0187308.
    PubMed     Abstract available


  542. FORCELLA M, Oldani M, Epistolio S, Freguia S, et al
    Non-small cell lung cancer (NSCLC), EGFR downstream pathway activation and TKI targeted therapies sensitivity: Effect of the plasma membrane-associated NEU3.
    PLoS One. 2017;12:e0187289.
    PubMed     Abstract available


  543. SCHMIDT LH, Heitkotter B, Schulze AB, Schliemann C, et al
    Prostate specific membrane antigen (PSMA) expression in non-small cell lung cancer.
    PLoS One. 2017;12:e0186280.
    PubMed     Abstract available


  544. OTOSHI T, Kataoka Y, Ikegaki S, Saito E, et al
    Pleural effusion biomarkers and computed tomography findings in diagnosing malignant pleural mesothelioma: A retrospective study in a single center.
    PLoS One. 2017;12:e0185850.
    PubMed     Abstract available


  545. ZHAO J, Dinkel J, Warth A, Penzel R, et al
    CT characteristics in pulmonary adenocarcinoma with epidermal growth factor receptor mutation.
    PLoS One. 2017;12:e0182741.
    PubMed     Abstract available


  546. LIU K, Zheng D, Xu G, Du Z, et al
    Local thoracic therapy improve prognosis for stage IV non-small cell lung cancer patients combined with chemotherapy: A Surveillance, Epidemiology, and End Results database analysis.
    PLoS One. 2017;12:e0187350.
    PubMed     Abstract available


  547. ARNS A, Blessing M, Fleckenstein J, Stsepankou D, et al
    Phantom-based evaluation of dose exposure of ultrafast combined kV-MV-CBCT towards clinical implementation for IGRT of lung cancer.
    PLoS One. 2017;12:e0187710.
    PubMed     Abstract available


  548. CHEN YF, Yuan A, Cho KH, Lu YC, et al
    Functional evaluation of therapeutic response of HCC827 lung cancer to bevacizumab and erlotinib targeted therapy using dynamic contrast-enhanced and diffusion-weighted MRI.
    PLoS One. 2017;12:e0187824.
    PubMed     Abstract available


  549. JABS V, Edlund K, Konig H, Grinberg M, et al
    Integrative analysis of genome-wide gene copy number changes and gene expression in non-small cell lung cancer.
    PLoS One. 2017;12:e0187246.
    PubMed     Abstract available


  550. FRENZEL T, Hoffmann B, Schmitz R, Bethge A, et al
    Radiotherapy and chemotherapy change vessel tree geometry and metastatic spread in a small cell lung cancer xenograft mouse tumor model.
    PLoS One. 2017;12:e0187144.
    PubMed     Abstract available


  551. SEO SR, Lee HM, Choi HS, Kim WT, et al
    Enhanced expression of cell-surface B-cell receptor-associated protein 31 contributes to poor survival of non-small cell lung carcinoma cells.
    PLoS One. 2017;12:e0188075.
    PubMed     Abstract available


  552. SIKDAR S, Datta S, Datta S
    EAMA: Empirically adjusted meta-analysis for large-scale simultaneous hypothesis testing in genomic experiments.
    PLoS One. 2017;12:e0187287.
    PubMed     Abstract available


  553. LIN CY, Wu YM, Hsieh MH, Wang CW, et al
    Prognostic implication of EGFR gene mutations and histological classification in patients with resected stage I lung adenocarcinoma.
    PLoS One. 2017;12:e0186567.
    PubMed     Abstract available


  554. JIAO DM, Yan L, Wang LS, Hu HZ, et al
    Retraction: Exploration of inhibitory mechanisms of curcumin in lung cancer metastasis using a miRNA- transcription factor-target gene network.
    PLoS One. 2017;12:e0189070.
    PubMed    


  555. LIU B, Zhao Y, Yuan J, Zeng L, et al
    Elevated N-telopeptide as a potential diagnostic marker for bone metastasis in lung cancer: A meta-analysis.
    PLoS One. 2017;12:e0187860.
    PubMed     Abstract available


  556. VAN RIEL SJ, Ciompi F, Winkler Wille MM, Dirksen A, et al
    Malignancy risk estimation of pulmonary nodules in screening CTs: Comparison between a computer model and human observers.
    PLoS One. 2017;12:e0185032.
    PubMed     Abstract available


  557. LI R, Zhang Y, Yuan Y, Lin Q, et al
    Dosimetric comparison of CT-guided iodine-125 seed stereotactic brachytherapy and stereotactic body radiation therapy in the treatment of NSCLC.
    PLoS One. 2017;12:e0187390.
    PubMed     Abstract available


  558. ZHOU S, Wang P, Su X, Chen J, et al
    High ECT2 expression is an independent prognostic factor for poor overall survival and recurrence-free survival in non-small cell lung adenocarcinoma.
    PLoS One. 2017;12:e0187356.
    PubMed     Abstract available


  559. MARCOS-VADILLO E, Garcia-Sanchez A, Sanz C, Davila I, et al
    PTGDR gene expression and response to dexamethasone treatment in an in vitro model.
    PLoS One. 2017;12:e0186957.
    PubMed     Abstract available


  560. ISAKSSON S, Jonsson P, Monsef N, Brunnstrom H, et al
    CA 19-9 and CA 125 as potential predictors of disease recurrence in resectable lung adenocarcinoma.
    PLoS One. 2017;12:e0186284.
    PubMed     Abstract available


  561. BRINKHOF S, Groen HJM, Siesling SS, IJzerman MJ, et al
    Resource utilization in lung cancer diagnostic procedures: Current use and budget consequences.
    PLoS One. 2017;12:e0189251.
    PubMed     Abstract available


  562. KIM ES, Baran AM, Mondo EL, Rodgers TD, et al
    Risk of thromboembolism in cisplatin versus carboplatin-treated patients with lung cancer.
    PLoS One. 2017;12:e0189410.
    PubMed     Abstract available


  563. ZHANG H, Diao H, Jia L, Yuan Y, et al
    Proteus mirabilis inhibits cancer growth and pulmonary metastasis in a mouse breast cancer model.
    PLoS One. 2017;12:e0188960.
    PubMed     Abstract available


  564. OOI CC, Mantalas GL, Koh W, Neff NF, et al
    High-throughput full-length single-cell mRNA-seq of rare cells.
    PLoS One. 2017;12:e0188510.
    PubMed     Abstract available


  565. KANG G, Liu K, Hou B, Zhang N, et al
    3D multi-view convolutional neural networks for lung nodule classification.
    PLoS One. 2017;12:e0188290.
    PubMed     Abstract available


  566. HAN KN, Kim HK, Choi YH
    Midterm outcomes of single port thoracoscopic surgery for major pulmonary resection.
    PLoS One. 2017;12:e0186857.
    PubMed     Abstract available


  567. KIM H, Park CM, Keam B, Park SJ, et al
    The prognostic value of CT radiomic features for patients with pulmonary adenocarcinoma treated with EGFR tyrosine kinase inhibitors.
    PLoS One. 2017;12:e0187500.
    PubMed     Abstract available


  568. GALLARDO-ESTRELLA L, Pompe E, de Jong PA, Jacobs C, et al
    Normalized emphysema scores on low dose CT: Validation as an imaging biomarker for mortality.
    PLoS One. 2017;12:e0188902.
    PubMed     Abstract available


  569. TAKAHASHI Y, Yasui T, Tamari K, Minami K, et al
    Radiation enhanced the local and distant anti-tumor efficacy in dual immune checkpoint blockade therapy in osteosarcoma.
    PLoS One. 2017;12:e0189697.
    PubMed     Abstract available


  570. SABIR SH, Krishnamurthy S, Gupta S, Mills GB, et al
    Characteristics of percutaneous core biopsies adequate for next generation genomic sequencing.
    PLoS One. 2017;12:e0189651.
    PubMed     Abstract available


    January 2016
  571. GOK DURNALI A, Paksoy Turkoz F, Ardic Yukruk F, Tokluoglu S, et al
    Outcomes of Adolescent and Adult Patients with Lung Metastatic Osteosarcoma and Comparison of Synchronous and Metachronous Lung Metastatic Groups.
    PLoS One. 2016;11:e0152621.
    PubMed     Abstract available


  572. ZHANG L, Qian H, Sha M, Luan Z, et al
    Downregulation of HOTAIR Expression Mediated Anti-Metastatic Effect of Artesunate on Cervical Cancer by Inhibiting COX-2 Expression.
    PLoS One. 2016;11:e0164838.
    PubMed     Abstract available


  573. FORGACS A, Pall Jonsson H, Dahlbom M, Daver F, et al
    A Study on the Basic Criteria for Selecting Heterogeneity Parameters of F18-FDG PET Images.
    PLoS One. 2016;11:e0164113.
    PubMed     Abstract available


  574. ZHANG L, Wang L, Tian P, Tian S, et al
    Identification of Genes Discriminating Multiple Sclerosis Patients from Controls by Adapting a Pathway Analysis Method.
    PLoS One. 2016;11:e0165543.
    PubMed     Abstract available


  575. APRELIKOVA O, Tomlinson CC, Hoenerhoff M, Hixon JA, et al
    Development and Preclinical Application of an Immunocompetent Transplant Model of Basal Breast Cancer with Lung, Liver and Brain Metastases.
    PLoS One. 2016;11:e0155262.
    PubMed     Abstract available


  576. SCHUSTER C, Akslen LA, Straume O
    Expression of Heat Shock Protein 27 in Melanoma Metastases Is Associated with Overall Response to Bevacizumab Monotherapy: Analyses of Predictive Markers in a Clinical Phase II Study.
    PLoS One. 2016;11:e0155242.
    PubMed     Abstract available


  577. SLADE RL, Pisaneschi F, Nguyen QD, Smith G, et al
    Identification of ABC Transporter Interaction of a Novel Cyanoquinoline Radiotracer and Implications for Tumour Imaging by Positron Emission Tomography.
    PLoS One. 2016;11:e0161427.
    PubMed     Abstract available


  578. WANG D, Zhang M, Gao X, Yu L, et al
    Prognostic Value of Baseline 18F-FDG PET/CT Functional Parameters in Patients with Advanced Lung Adenocarcinoma Stratified by EGFR Mutation Status.
    PLoS One. 2016;11:e0158307.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: